Encompass Health (EHC) 10-Q 1 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 23, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	ENCOMPASS HEALTH CORP
Entity Central Index Key	0000785161
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		98,852,589
Entity Current Reporting Status	Yes

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net operating revenues	$ 1,124	$ 1,046
Operating expenses:
Salaries and benefits	620.8	570.2
Other operating expenses	150.1	141.2
Occupancy costs	19.6	18.6
Supplies	40.1	39.9
General and administrative expenses	53.4	61.1
Depreciation and amortization	52.5	45.9
Total operating expenses	936.5	876.9
Interest expense and amortization of debt discounts and fees	37.2	35.6
Other (income) loss	(3.7)	0.1
Equity in net income of nonconsolidated affiliates	(2.5)	(2.3)
Income from continuing operations before income tax expense	156.5	135.7
Provision for income tax expense	30.8	30
Income from continuing operations	125.7	105.7
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net and comprehensive income	125.2	105.2
Less: Net and comprehensive income attributable to noncontrolling interests	(22.9)	(21.4)
Net and comprehensive income attributable to Encompass Health	$ 102.3	$ 83.8
Weighted average common shares outstanding:
Basic (shares)	98.4	97.8
Diluted (shares)	99.7	99.4
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.05	$ 0.86
Discontinued operations (in dollars per share)	(0.01)	(0.01)
Net Income (in dollars per share)	1.04	0.85
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	1.04	0.85
Discontinued operations (in dollars per share)	(0.01)	(0.01)
Net income (in dollars per share)	$ 1.03	$ 0.84
Amounts attributable to Encompass Health common shareholders:
Income from continuing operations	$ 102.8	$ 84.3
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net and comprehensive income attributable to Encompass Health	$ 102.3	$ 83.8

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2019		Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 56.1		$ 69.2	$ 86.4	$ 54.4
Restricted cash	59		59	69.4	62.4
Accounts receivable	500.6		467.7
Other current assets	67		66.2
Total current assets	682.7		662.1
Property and equipment, net	1,736.2		1,634.8
Operating lease right-of-use assets	284.9		0
Goodwill	2,111.6		2,100.8
Intangible assets, net	435.4		443.4
Deferred income tax assets	40.5		42.9
Other long-term assets	292.5		291
Total assets	5,583.8	[1]	5,175
Current liabilities:
Current portion of long-term debt	37.3		35.8
Current operating lease liabilities	48.3		0
Accounts payable	94.7		90
Accrued expenses and other current liabilities	587.9		546.7
Total current liabilities	768.2		672.5
Long-term debt, net of current portion	2,521.8		2,478.6
Long-term operating lease liabilities	245		0
Other long-term liabilities	159.3		205.2
Total Liabilities	3,694.3		3,356.3
Commitments and contingencies
Redeemable noncontrolling interests	273		261.7
Shareholders’ equity:
Encompass Health shareholders’ equity	1,314.3		1,276.7
Noncontrolling interests	302.2		280.3
Total shareholders’ equity	1,616.5		1,557	$ 1,409.9	$ 1,395.4
Total liabilities and shareholders' equity	$ 5,583.8	[1]	$ 5,175
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Total assets of variable interest entities	$ 216.2	$ 197.5
Total liabilities of variable interest entities	$ 62.2	$ 50.8

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2017	$ 1,395.4	$ 1.1	$ 2,747.4	$ (1,176.2)	$ (1.3)	$ (418.5)	$ 242.9
Balance at beginning of period (shares) at Dec. 31, 2017		98.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	102.4			83.8			18.6
Receipt of treasury stock	(8.3)					(8.3)
Receipt of treasury stock (shares)		(0.2)
Dividends declared ($0.27 per share)	(24.9)		(24.9)
Stock-based compensation	5.3		5.3
Distributions declared	(17.7)						(17.7)
Fair value adjustments to redeemable noncontrolling interests, net of tax	(42.2)		(42.2)
Other	(0.1)	$ 0	0.3	(1.3)	1.3	(0.4)	0
Other (shares)		0.7
Balance at end of period at Mar. 31, 2018	1,409.9	$ 1.1	2,685.9	(1,093.7)	0	(427.2)	243.8
Balance at end of period (shares) at Mar. 31, 2018		98.8
Balance at beginning of period at Dec. 31, 2018	1,557	$ 1.1	2,588.7	(885.2)	0	(427.9)	280.3
Balance at beginning of period (shares) at Dec. 31, 2018		98.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	121.2			102.3			18.9
Receipt of treasury stock	(15.9)					(15.9)
Receipt of treasury stock (shares)		(0.3)
Dividends declared ($0.27 per share)	(26.9)		(26.9)
Stock-based compensation	7		7
Distributions declared	(15.3)						(15.3)
Capital contributions from consolidated affiliates	7.1						7.1
Fair value adjustments to redeemable noncontrolling interests, net of tax	(20.3)		(20.3)
Repurchases of common stock in open market	(11)					(11)
Repurchases of common stock in open market (shares)		(0.2)
Other	13.6		2.8	0	0	(0.4)	11.2
Other (shares)		0.7
Balance at end of period at Mar. 31, 2019	$ 1,616.5	$ 1.1	$ 2,551.3	$ (782.9)	$ 0	$ (455.2)	$ 302.2
Balance at end of period (shares) at Mar. 31, 2019		99.1

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Stockholders' Equity (Parenthetical) [Abstract]
Dividends declared on common stock	$ 0.27	$ 0.25

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income	$ 125.2	$ 105.2
Loss from discontinued operations, net of tax	0.5	0.5
Adjustments to reconcile net income to net cash provided by operating activities—
Depreciation and amortization	52.5	45.9
Stock-based compensation	19.4	26.1
Deferred tax expense (benefit)	2.6	(3)
Other, net	(0.8)	1.6
Change in assets and liabilities, net of acquisitions—
Accounts receivable	(29.6)	8.3
Other assets	(3.8)	14.2
Accrued payroll	(14.8)	(9.5)
Other liabilities	11.7	27.7
Net cash used in operating activities of discontinued operations	(3)	(0.7)
Total adjustments	34.2	110.6
Net cash provided by operating activities	159.9	216.3
Cash flows from investing activities:
Purchases of property and equipment	(72.3)	(59.9)
Acquisitions of businesses, net of cash acquired	(13.7)	(0.6)
Other, net	(5.5)	(0.1)
Net cash used in investing activities	(91.5)	(60.6)
Cash flows from financing activities:
Borrowings on revolving credit facility	25	95
Payments on revolving credit facility	(30)	(95)
Dividends paid on common stock	(28.3)	(25.4)
Purchase of equity interests in consolidated affiliates	0	(65.1)
Distributions paid to noncontrolling interests of consolidated affiliates	(19.5)	(15.4)
Taxes paid on behalf of employees for shares withheld	(15.9)	(8.3)
Other, net	(13)	(2.5)
Net cash used in financing activities	(81.7)	(116.7)
(Decrease) increase in cash, cash equivalents, and restricted cash	(13.3)	39
Cash, cash equivalents, and restricted cash at beginning of period	133.5	116.8
Cash, cash equivalents, and restricted cash at end of period	120.2	155.8
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period	69.2	54.4
Restricted cash at beginning of period	59	62.4
Restricted cash included in other long-term assets at beginning of period	5.3	0
Cash, cash equivalents, and restricted cash at beginning of period	133.5	116.8
Cash and cash equivalents at end of period	56.1	86.4
Restricted cash at end of period	59	69.4
Restricted cash included in other long-term assets at end of period	5.1	0
Cash, cash equivalents, and restricted cash at end of period	$ 120.2	$ 155.8

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based patient services in 37 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 12 , Segment Reporting . The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on February 27, 2019 (the “ 2018 Form 10‑K ”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2018 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Net Operating Revenues — Our Net operating revenues disaggregated by payor source and segment are as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Consolidated Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, 2019 2018 2019 2018 2019 2018 Medicare $ 638.9 $ 624.5 $ 214.8 $ 176.9 $ 853.7 $ 801.4 Medicare Advantage 85.2 72.5 25.5 20.0 110.7 92.5 Managed care 83.5 85.0 8.4 7.6 91.9 92.6 Medicaid 26.2 24.7 4.3 0.5 30.5 25.2 Other third-party payors 10.0 12.0 — — 10.0 12.0 Workers’ compensation 8.2 7.4 0.2 0.1 8.4 7.5 Patients 6.1 4.4 0.4 0.4 6.5 4.8 Other income 12.0 9.8 0.3 0.2 12.3 10.0 Total $ 870.1 $ 840.3 $ 253.9 $ 205.7 $ 1,124.0 $ 1,046.0 See Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2018 Form 10-K for our policy related to Net operating revenues . Leases— We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and nonlease components separately for purposes of establishing right-of-use assets and lease liabilities. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term. Recently Adopted Accounting Pronouncements — In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” and has subsequently issued supplemental and/or clarifying ASUs (collectively “ASC 842”), in order to increase transparency and comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. We adopted ASC 842 using the modified retrospective approach and applied the transition provisions with an effective date as of January 1, 2019 for leases that existed on that date. Prior period results continue to be presented under ASC 840 based on the accounting originally in effect for such periods. ASC 842 provides optional practical expedients in transition. We elected the ‘package of practical expedients,’ which permits us to not reassess under ASC 842 our prior conclusions about lease identification, lease classification and initial direct costs, and the practical expedient to not reassess certain land easements. We did not elect the use-of-hindsight practical expedient during the transition to ASC 842. The adoption of ASC 842 resulted in the addition of approximately $349 million in assets and $347 million in liabilities to our condensed consolidated balance sheet as of January 1, 2019, with the remaining $2 million being recorded as an adjustment to Capital in excess of par value . The adoption of ASC 842 also resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of cash flows arising from leases. See the “Leases” section of this note and Note 4, Leases , for additional information about our leases. Recent Accounting Pronouncements Not Yet Adopted — In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326),” which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance is effective for us beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted beginning January 1, 2019. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance is effective for us beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows. Revision of Previously Issued Financial Statements — During the preparation of our December 31, 2018 financial statements, an error was identified in the accounting for deferred tax assets related to fair value adjustments to redeemable noncontrolling interests. At that time, we assessed the materiality of the errors in deferred tax assets and related balances and concluded they were not material to any previously issued financial statements or disclosures. However, we revised our previously issued annual financial statements in connection with the issuance of our 2018 financial statements to correct for such errors. In addition, we have revised our condensed consolidated statement of shareholders’ equity for the three months ended March 31, 2018 presented herein to reflect the correction of these errors, which originated in years prior to 2018, as disclosed in the table below. For additional information on this revision, see Note 1, Summary of Significant Accounting Policies , “Revision of Previously Issued Financial Statements” to the consolidated financial statements accompanying the 2018 Form 10-K. As Reported Adjustment As Revised For the Three Months Ended March 31, 2018 (In Millions) Fair value adjustments to redeemable noncontrolling interests $ (40.5 ) $ (1.7 ) $ (42.2 ) Capital in excess of par value 2,731.6 (45.7 ) 2,685.9 Accumulated deficit (1,108.5 ) 14.8 (1,093.7 ) Total shareholders’ equity 1,440.8 (30.9 ) 1,409.9

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Business Combinations	Business Combinations Home Health and Hospice Alacare Acquisition In March 2019, we signed a definitive agreement to purchase substantially all of the assets of privately owned Alacare Home Health & Hospice (“Alacare”) for a cash purchase price of approximately $217.5 million . Alacare operates 23 home health locations and 23 hospice locations in Alabama. This transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in June 2019. We expect to fund the transaction with cash on hand and borrowings under our revolving credit facility. Other Home Health and Hospice Acquisitions During the three months ended March 31, 2019 , we completed the following home health and hospice acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded using cash on hand. • In February 2019, we acquired the assets of Tidewater Home Health, PA in Columbia, South Carolina. • In March 2019, we acquired the assets and assumed the liabilities of two home health locations from Care Resource Group in East Providence, Rhode Island and Westport, Massachusetts. We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using an income approach. The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations’ mobile workforce and established relationships within each community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. All goodwill recorded as a result of these transactions is deductible for federal income tax purposes. The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Identifiable intangible assets: Noncompete agreements (useful lives of 5 years) $ 0.2 Certificates of need (useful lives of 10 years) 2.0 License (useful life of 10 years) 0.8 Goodwill 10.8 Other assets acquired 0.2 Total assets acquired 14.0 Liabilities assumed: Accrued payroll (0.1 ) Other current liabilities (0.1 ) Other long-term liabilities (0.1 ) Total liabilities assumed (0.3 ) Net assets acquired $ 13.7 Information regarding the net cash paid for the other home health and hospice acquisitions during each period presented is as follows (in millions): Three Months Ended March 31, 2019 2018 Fair value of assets acquired $ 3.2 $ 0.1 Goodwill 10.8 0.5 Fair value of liabilities assumed (0.3 ) — Net cash paid for acquisitions $ 13.7 $ 0.6 Pro Forma Results of Operations The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2018 (in millions): Net Operating Revenues Net Income Attributable to Encompass Health Acquired entities only: Actual from acquisition date to March 31, 2019 Home Health and Hospice $ 1.0 $ (0.1 ) Combined entity: Supplemental pro forma from 01/01/2019-03/31/2019 1,126.0 102.5 Combined entity: Supplemental pro forma from 01/01/2018-03/31/2018 1,048.4 84.0 The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2018 reporting period. See Note 2, Business Combinations , to the consolidated financial statements accompanying the 2018 Form 10‑K for information regarding acquisitions completed in 2018.

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities As of March 31, 2019 and December 31, 2018 , we consolidated eight limited partnership-like entities that are variable interest entities (“VIEs”) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% . Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities. The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions): March 31, 2019 December 31, 2018 Assets Current assets: Cash and cash equivalents $ 0.7 $ 0.3 Accounts receivable 31.0 31.0 Other current assets 5.9 4.9 Total current assets 37.6 36.2 Property and equipment, net 121.2 111.5 Operating lease right-of-use assets 7.2 — Goodwill 15.9 15.9 Intangible assets, net 4.0 4.3 Other long-term assets 30.3 29.6 Total assets $ 216.2 $ 197.5 Liabilities Current liabilities: Current portion of long-term debt $ 0.7 $ 0.6 Current operating lease liabilities 1.4 — Accounts payable 5.6 5.2 Accrued expenses and other current liabilities 37.7 45.0 Total current liabilities 45.4 50.8 Long-term debt, net of current portion 11.1 — Long-term operating lease liabilities 5.7 — Total liabilities $ 62.2 $ 50.8

Leases Leases

Leases Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases of Lessee Disclosure	Leases We lease real estate, vehicles, and equipment under operating and finance leases with non-canceable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1 - to 25 -year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be negotiated at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property. The components of lease costs are as follows (in millions): Three Months Ended March 31, 2019 Operating lease cost $ 17.5 Finance lease cost: Amortization of right-of-use assets 11.9 Interest on lease liabilities 8.1 Total finance lease cost 20.0 Short-term and variable lease cost 0.3 Sublease income (0.8 ) Total lease cost $ 37.0 Supplemental condensed consolidated balance sheet information related to leases is as follows (in millions): Classification As of March 31, 2019 Assets Operating lease Operating lease right-of-use assets $ 284.9 Finance lease (1) Property and equipment, net 344.0 Total leased assets $ 628.9 Liabilities Current liabilities: Operating lease Current operating lease liabilities $ 48.3 Finance lease Current portion of long-term debt 18.2 Noncurrent liabilities: Operating lease Long-term operating lease liabilities 245.0 Finance lease Long-term debt, net of current portion 381.9 Total leased liabilities $ 693.4 (1) Finance lease assets are recorded net of accumulated amortization of $95.6 million as of March 31, 2019. As of March 31, 2019 Weighted Average Remaining Lease Term Operating lease 8.6 years Finance lease 13.5 years Weighted Average Discount Rate Operating lease 6.3 % Finance lease 8.2 % Maturities of lease liabilities as of March 31, 2019 are as follows (in millions): Operating Leases Finance Leases April 1 through December 31, 2019 $ 48.1 $ 37.8 2020 58.6 49.9 2021 51.0 48.0 2022 40.8 57.6 2023 35.4 43.7 2024 31.3 58.1 2025 and Thereafter 129.7 391.4 Total lease payments 394.9 686.5 Less: Interest portion (101.6 ) (286.4 ) Total lease liabilities $ 293.3 $ 400.1 Future minimum lease payments at December 31, 2018, for those leases having an initial or remaining noncancelable lease term in excess of one year, are as follows (in millions): Year Ending December 31, Operating Leases Capital Lease Obligations 2019 $ 71.4 $ 36.2 2020 65.8 32.3 2021 54.3 30.3 2022 41.0 28.7 2023 35.3 28.0 2024 and Thereafter 148.2 299.7 $ 416.0 455.2 Less: Interest portion (191.4 ) Obligations under capital leases $ 263.8 Supplemental cash flow information related to our leases is as follows (in millions): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 17.2 Operating cash flows from finance leases 8.0 Financing cash flows from finance leases 2.8 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 5.5 Finance leases 3.1

Investments in and Advances to

Investments in and Advances to Nonconsolidated Affiliates	3 Months Ended
	Mar. 31, 2019
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Investments in and Advances to Nonconsolidated Affiliates	Investments in and Advances to Nonconsolidated Affiliates As of March 31, 2019 and December 31, 2018 , we had $12.5 million and $12.2 million , respectively, of investments in and advances to nonconsolidated affiliates included in Other long-term assets in our condensed consolidated balance sheets. Investments in and advances to nonconsolidated affiliates represent our investments in five partially owned subsidiaries, of which four are general or limited partnerships, limited liability companies, or joint ventures in which Encompass Health or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 19% to 60% . We account for these investments using the cost and equity methods of accounting. The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended March 31, 2019 2018 Net operating revenues $ 11.6 $ 11.0 Operating expenses (6.8 ) (7.6 ) Income from continuing operations, net of tax 4.9 3.4 Net income 4.9 3.4

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	3 Months Ended
	Mar. 31, 2019
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests The following is a summary of the activity related to our Redeemable noncontrolling interests during the three months ended March 31, 2019 and 2018 (in millions): Three Months Ended March 31, 2019 2018 Balance at beginning of period $ 261.7 $ 220.9 Net income attributable to noncontrolling interests 4.0 2.8 Distributions declared (1.8 ) (2.2 ) Reclassification to noncontrolling interests (11.2 ) — Purchase of redeemable noncontrolling interests — (65.1 ) Change in fair value 20.3 42.2 Balance at end of period $ 273.0 $ 198.6 The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of comprehensive income for the three months ended March 31, 2019 and 2018 (in millions): Three Months Ended March 31, 2019 2018 Net income attributable to nonredeemable noncontrolling interests $ 18.9 $ 18.6 Net income attributable to redeemable noncontrolling interests 4.0 2.8 Net income attributable to noncontrolling interests $ 22.9 $ 21.4 On December 31, 2014, we acquired 83.3% of our home health and hospice business when we purchased EHHI Holdings, Inc. (“EHHI”). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (“Holdings”), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor has the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. Specifically, up to one-third of each management investor’s shares of Holdings stock may be sold prior to December 31, 2018; two-thirds of each management investor’s shares of Holdings stock may be sold prior to December 31, 2019; and all of each management investor’s shares of Holdings stock may be sold thereafter. At any time after December 31, 2019, Encompass Health will have the right (but not the obligation) to repurchase all or any portion of the shares of Holdings stock owned by one or more management investors for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February 21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. As of March 31, 2019 , the value of the outstanding shares of Holdings owned by management investors was approximately $245 million . See also Note 7 , Fair Value Measurements .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of March 31, 2019 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other long-term assets: Restricted marketable securities $ 63.6 $ 6.7 $ 56.9 $ — M Redeemable noncontrolling interests 273.0 — — 273.0 I As of December 31, 2018 Other long-term assets: Restricted marketable securities $ 62.0 $ 6.4 $ 55.6 $ — M Redeemable noncontrolling interests 261.7 — — 261.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I). The fair values of our financial assets and liabilities are determined as follows: • Restricted marketable securities - The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. • Redeemable noncontrolling interests - The fair value of the Redeemable noncontrolling interests related to our home health segment is determined using the product of a twelve-month adjusted EBITDA measure and a specified median market price multiple based on a basket of public home health companies and transactions, after adding cash and deducting indebtedness that includes the outstanding principal balance under any intercompany notes. To determine the fair value of the Redeemable noncontrolling interests in our joint venture hospitals, we use the applicable hospitals’ projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management’s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures. See also Note 6 , Redeemable Noncontrolling Interests . In addition to assets and liabilities recorded at fair value on a recurring basis, we are also required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets. During the three months ended March 31, 2019 and March 31, 2018 , we did not record any gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations. As discussed in Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2018 Form 10‑K , the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of March 31, 2019 As of December 31, 2018 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 25.0 $ 25.0 $ 30.0 $ 30.0 Term loan facilities 276.4 277.5 280.1 281.3 5.125% Senior Notes due 2023 296.8 305.3 296.6 298.5 5.75% Senior Notes due 2024 1,194.8 1,221.0 1,194.7 1,200.0 5.75% Senior Notes due 2025 345.2 357.9 345.0 339.5 Other notes payable 20.8 20.8 104.2 104.2 Financial commitments: Letters of credit — 39.1 — 37.4 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2018 Form 10‑K .

Share-Based Payments

Share-Based Payments	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments In February 2019 , we issued a total of 0.4 million restricted stock awards to members of our management team and our board of directors. Approximately 0.1 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable two -year performance measurement period. Additionally, in February 2019 , we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies , and Note 13, Share-Based Payments , to the consolidated financial statements accompanying the 2018 Form 10‑K . In conjunction with the EHHI acquisition discussed in Note 6 , Redeemable Noncontrolling Interests , we granted stock appreciation rights (“SARs”) based on Holdings common stock to certain members of EHHI management at closing. Half of the SARs vested on December 31, 2018 with the remainder vesting on December 31, 2019. Upon exercise, each SAR must be settled for cash in the amount by which the per share fair value of Holdings’ common stock on the exercise date exceeds the per share fair value on the grant date. In February 2019, members of the management team exercised a portion of their vested SARs for approximately $13 million in cash. As of March 31, 2019 , the fair value of the SARs is approximately $86 million , all of which is included in Accrued expenses and other current liabilities in the condensed consolidated balance sheet. For additional information, see Note 13, Share-Based Payments , to the consolidated financial statements accompanying the 2018 Form 10‑K .

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our Provision for income tax expense of $30.8 million and $30.0 million for the three months ended March 31, 2019 and 2018, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate and share-based windfall tax benefits. We have state net operating losses (“NOLs”) of $64.5 million that expire in various amounts at varying times through 2031. The $40.5 million of net deferred tax assets included in the accompanying condensed consolidated balance sheet as of March 31, 2019 reflects management’s assessment it is more likely than not we will be able to generate sufficient future taxable income to utilize those deferred tax assets based on our current estimates and assumptions. As of March 31, 2019 , we maintained a valuation allowance of $34.5 million due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management’s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates. During the third quarter of 2016, we filed a non-automatic tax accounting method change related to billings denied under pre-payment claims reviews conducted by certain of our MACs. In March 2017, the IRS approved our request resulting in additional cash tax benefits of approximately $51.3 million through December 31, 2017. These benefits are expected to reverse as pre-payment claims denials are settled and collected. This change did not have a material impact on our effective tax rate. The 2017 Tax Cuts and Jobs Act (the “Tax Act”) included revisions to Internal Revenue Code §451 that may eliminate this deferral of revenue for tax purposes. We are currently evaluating this provision of the Tax Act and its future impact on the method change we received in March 2017. Total remaining gross unrecognized tax benefits were $0.9 million as of March 31, 2019 and December 31, 2018 , respectively, all of which would affect our effective tax rate if recognized. Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during the three months ended March 31, 2019 and 2018 was not material. Accrued interest income related to income taxes as of March 31, 2019 and December 31, 2018 was not material. In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (“CAP”) for the 2017 tax year. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. We renewed this agreement in January 2018 for the 2018 tax year and in December 2018 for the 2019 tax year. As a result of these agreements, the IRS is currently examining the 2017, 2018 and 2019 tax years. In May 2018, the IRS issued a no-change Revenue Agent’s Report effectively closing our 2016 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2016. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by one state for tax years ranging from 2013 through 2015. For the tax years that remain open under the applicable statutes of limitation, amounts related to unrecognized tax benefits have been considered by management in its estimate of our potential net recovery of prior years’ income taxes. Based on discussions with taxing authorities, we anticipate that approximately $0.5 million of our unrecognized tax benefits will be released within the next 12 months.

Earnings per Common Share

Earnings per Common Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended March 31, 2019 2018 Basic: Numerator: Income from continuing operations $ 125.7 $ 105.7 Less: Net income attributable to noncontrolling interests included in continuing operations (22.9 ) (21.4 ) Less: Income allocated to participating securities (0.4 ) (0.3 ) Income from continuing operations attributable to Encompass Health common shareholders 102.4 84.0 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders (0.5 ) (0.5 ) Net income attributable to Encompass Health common shareholders $ 101.9 $ 83.5 Denominator: Basic weighted average common shares outstanding 98.4 97.8 Basic earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.05 $ 0.86 Discontinued operations (0.01 ) (0.01 ) Net income $ 1.04 $ 0.85 Diluted: Numerator: Income from continuing operations $ 125.7 $ 105.7 Less: Net income attributable to noncontrolling interests included in continuing operations (22.9 ) (21.4 ) Income from continuing operations attributable to Encompass Health common shareholders 102.8 84.3 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders (0.5 ) (0.5 ) Net income attributable to Encompass Health common shareholders $ 102.3 $ 83.8 Denominator: Diluted weighted average common shares outstanding 99.7 99.4 Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.04 $ 0.85 Discontinued operations (0.01 ) (0.01 ) Net income $ 1.03 $ 0.84 The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended March 31, 2019 2018 Basic weighted average common shares outstanding 98.4 97.8 Restricted stock awards, dilutive stock options, and restricted stock units 1.3 1.6 Diluted weighted average common shares outstanding 99.7 99.4 In October 2018 and February 2019, our board of directors declared cash dividends of $0.27 per share that were paid in January and April 2019, respectively. As of March 31, 2019 and December 31, 2018 , accrued common stock dividends of $27.8 million and $28.4 million , respectively, were included in Accrued expenses and other current liabilities in our condensed consolidated balance sheets. Future dividend payments are subject to declaration by our board of directors. See Note 16, Earnings per Common Share , to the consolidated financial statements accompanying the 2018 Form 10‑K for additional information related to our common stock.

Contingencies and Other Commitm

Contingencies and Other Commitments	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. Nichols Litigation— We were named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp . The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was stayed in the circuit court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against Encompass Health and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims were derivative in nature, and the claims were time-barred by the statute of limitations. On May 26, 2016, the court granted our motion to dismiss. The plaintiffs appealed the dismissal of the case to the Supreme Court of Alabama on June 28, 2016. On March 23, 2018, the Alabama Supreme Court reversed the trial court’s dismissal, holding that the plaintiffs’ claims were not derivative or time-barred, and remanded the case for further proceedings. On April 6, 2018, we filed an application for rehearing with the Alabama Supreme Court. On March 22, 2019, the Alabama Supreme Court denied our application for rehearing and remanded the case to the trial court for further proceedings. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. Other Litigation— One of our hospital subsidiaries was named as a defendant in a lawsuit filed August 12, 2013 by an individual in the Circuit Court of Etowah County, Alabama, captioned Honts v. HealthSouth Rehabilitation Hospital of Gadsden, LLC. The plaintiff alleged that her mother, who died more than three months after being discharged from our hospital, received an unprescribed opiate medication at the hospital. We deny the patient received any such medication, accounted for all the opiates at the hospital and argued the plaintiff established no causal liability between the actions of our staff and her mother’s death. The plaintiff sought recovery for punitive damages. On May 18, 2016, the jury in this case returned a verdict in favor of the plaintiff for $20.0 million . On June 17, 2016, we filed a renewed motion for judgment as a matter of law or, in the alternative, a motion for new trial or, in the further alternative, a motion seeking reduction of the damages awarded (collectively, the “post-judgment motions”). The trial court denied the post-judgment motions. We appealed the verdict as well as the rulings on the post-judgment motions to the Supreme Court of Alabama on October 12, 2016. On September 28, 2018, the Alabama Supreme Court reversed the trial court’s judgment and remanded the case for a new trial. On October 12, 2018, the plaintiff filed an application for rehearing with the Alabama Supreme Court, and we filed a brief in opposition to the rehearing application on October 25, 2018. As a result of the Alabama Supreme Court’s reversal, we reduced the associated liability below our insurance retention level of $6.0 million , and no longer maintained an insurance receivable in our condensed consolidated balance sheet because we believed the liability did not exceed that retention level. As of December 31, 2018, we maintained a liability included in Accrued expenses and other current liabilities in our consolidated balance sheet in connection with this matter. On February 27, 2019, we entered into a settlement with the plaintiff for an amount less than the remaining liability reserved and not material to us. Governmental Inquiries and Investigations— On March 4, 2013, we received document subpoenas from an office of the United States Department of Health and Human Services Office of Inspector General (the “HHS-OIG”) addressed to four of our hospitals. Those subpoenas also requested complete copies of medical records for 100 patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional 70 patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. We have not received any subsequent requests for medical records from the DOJ. All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the “ 60% rule,” an inpatient rehabilitation hospital must treat 60% or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. We have been cooperating fully with DOJ in connection with this investigation. Based on recent discussions with the government as well as the burdens and distractions associated with continuing the investigation and the likely costs of future litigation, we now estimate a settlement value of $48 million and have accrued a loss contingency in that amount which is included in Accrued expenses and other current liabilities in our condensed consolidated balance sheet. Discussions are ongoing, and until they are concluded, there can be no certainty about the nature, timing or likelihood of a settlement. Other Matters— The False Claims Act allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as “whistleblower” or “ qui tam ” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. Qui tam cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a qui tam action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act. It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Inpatient Rehabilitation - Our national network of inpatient rehabilitation hospitals stretches across 32 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of March 31, 2019 , we operate 130 inpatient rehabilitation hospitals, including one hospital that operates as a joint venture which we account for using the equity method of accounting. We are the sole owner of 85 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 45 jointly owned hospitals. In addition, we manage five inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. • Home Health and Hospice - As of March 31, 2019 , we provide home health services in 221 locations and hospice services in 59 locations across 31 states with concentrations in the Southeast and Texas. In addition, two of these agencies operate as joint ventures which we account for using the equity method of accounting. We are the sole owner of 272 of these locations. We retain 50.0% to 81.0% ownership in the remaining eight jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Basis of Presentation , “Leases” to these condensed consolidated financial statements and Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2018 Form 10‑K . All revenues for our services are generated through external customers. See Note 1 , Basis of Presentation , “Net Operating Revenues,” for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended March 31, Three Months Ended March 31, 2019 2018 2019 2018 Net operating revenues $ 870.1 $ 840.3 $ 253.9 $ 205.7 Operating expenses: Inpatient rehabilitation: Salaries and benefits 445.0 424.2 — — Other operating expenses 127.6 122.9 — — Supplies 35.6 35.9 — — Occupancy costs 15.8 15.5 — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — 116.5 98.6 Support and overhead costs — — 88.8 72.0 624.0 598.5 205.3 170.6 Other income (2.8 ) (0.5 ) — — Equity in net income of nonconsolidated affiliates (2.1 ) (2.0 ) (0.4 ) (0.3 ) Noncontrolling interests 21.0 20.5 2.7 1.9 Segment Adjusted EBITDA $ 230.0 $ 223.8 $ 46.3 $ 33.5 Capital expenditures $ 70.4 $ 62.2 $ 4.5 $ 1.7 Inpatient Rehabilitation Home Health and Hospice Encompass Health Consolidated As of March 31, 2019 Total assets $ 4,250.5 $ 1,366.8 $ 5,583.8 Investments in and advances to nonconsolidated affiliates 9.4 3.1 12.5 As of December 31, 2018 Total assets $ 3,900.9 $ 1,314.6 $ 5,175.0 Investments in and advances to nonconsolidated affiliates 9.5 2.7 12.2 Segment reconciliations (in millions): Three Months Ended March 31, 2019 2018 Total segment Adjusted EBITDA $ 276.3 $ 257.3 General and administrative expenses (53.4 ) (61.1 ) Depreciation and amortization (52.5 ) (45.9 ) Loss on disposal of assets (1.1 ) (0.8 ) Interest expense and amortization of debt discounts and fees (37.2 ) (35.6 ) Net income attributable to noncontrolling interests 22.9 21.4 SARs mark-to-market impact on noncontrolling interests 0.8 1.0 Change in fair market value of equity securities 0.9 (0.6 ) Payroll taxes on SARs exercise (0.2 ) — Income from continuing operations before income tax expense $ 156.5 $ 135.7 March 31, 2019 December 31, 2018 Total assets for reportable segments $ 5,617.3 $ 5,215.5 Reclassification of deferred income tax liabilities to net deferred income tax assets (33.5 ) (40.5 ) Total consolidated assets $ 5,583.8 $ 5,175.0 Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended March 31, 2019 2018 Inpatient rehabilitation: Inpatient $ 847.6 $ 817.1 Outpatient and other 22.5 23.2 Total inpatient rehabilitation 870.1 840.3 Home health and hospice: Home health 219.5 185.3 Hospice 34.4 20.4 Total home health and hospice 253.9 205.7 Total net operating revenues $ 1,124.0 $ 1,046.0

Condensed Consolidating Financi

Condensed Consolidating Financial Information	3 Months Ended
	Mar. 31, 2019
Condensed Financial Information Disclosure [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Each of the subsidiary guarantors is 100% owned by Encompass Health, and all guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. Encompass Health’s investments in its consolidated subsidiaries, as well as guarantor subsidiaries’ investments in nonguarantor subsidiaries and nonguarantor subsidiaries’ investments in guarantor subsidiaries, are presented under the equity method of accounting with the related investment presented within the line items Intercompany receivable and investments in consolidated affiliates and Intercompany payable in the accompanying condensed consolidating balance sheets. The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2 x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2 x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 9, Long-term Debt , to the consolidated financial statements accompanying the 2018 Form 10‑K . Periodically, certain wholly owned subsidiaries of Encompass Health make dividends or distributions of available cash and/or intercompany receivable balances to their parents. In addition, Encompass Health makes contributions to certain wholly owned subsidiaries. When made, these dividends, distributions, and contributions impact the Intercompany receivable and investments in consolidated affiliates , Intercompany payable , and Encompass Health shareholders’ equity line items in the accompanying condensed consolidating balance sheet but have no impact on the consolidated financial statements of Encompass Health Corporation. Three Months Ended March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net operating revenues $ 5.1 $ 606.5 $ 546.0 $ (33.6 ) $ 1,124.0 Operating expenses: Salaries and benefits 15.9 288.9 321.1 (5.1 ) 620.8 Other operating expenses 10.3 84.7 67.6 (12.5 ) 150.1 Occupancy costs 0.5 24.9 10.2 (16.0 ) 19.6 Supplies — 24.0 16.1 — 40.1 General and administrative expenses 39.9 — 13.5 — 53.4 Depreciation and amortization 5.0 26.3 21.2 — 52.5 Total operating expenses 71.6 448.8 449.7 (33.6 ) 936.5 Interest expense and amortization of debt discounts and fees 30.1 6.2 7.7 (6.8 ) 37.2 Other income (7.7 ) (0.3 ) (2.5 ) 6.8 (3.7 ) Equity in net income of nonconsolidated affiliates — (2.1 ) (0.4 ) — (2.5 ) Equity in net income of consolidated affiliates (130.2 ) (17.0 ) — 147.2 — Management fees (39.8 ) 29.5 10.3 — — Income from continuing operations before income tax (benefit) expense 81.1 141.4 81.2 (147.2 ) 156.5 Provision for income tax (benefit) expense (21.7 ) 37.8 14.7 — 30.8 Income from continuing operations 102.8 103.6 66.5 (147.2 ) 125.7 Loss from discontinued operations, net of tax (0.5 ) — — — (0.5 ) Net and comprehensive income 102.3 103.6 66.5 (147.2 ) 125.2 Less: Net and comprehensive income attributable to noncontrolling interests — — (22.9 ) — (22.9 ) Net and comprehensive income attributable to Encompass Health $ 102.3 $ 103.6 $ 43.6 $ (147.2 ) $ 102.3 Three Months Ended March 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net operating revenues $ 5.4 $ 594.6 $ 478.6 $ (32.6 ) $ 1,046.0 Operating expenses: Salaries and benefits 13.2 282.4 280.0 (5.4 ) 570.2 Other operating expenses 8.4 84.6 60.6 (12.4 ) 141.2 Occupancy costs 0.5 23.8 9.1 (14.8 ) 18.6 Supplies — 24.7 15.2 — 39.9 General and administrative expenses 39.4 — 21.7 — 61.1 Depreciation and amortization 2.0 26.6 17.3 — 45.9 Total operating expenses 63.5 442.1 403.9 (32.6 ) 876.9 Interest expense and amortization of debt discounts and fees 29.8 5.7 5.2 (5.1 ) 35.6 Other (income) loss (4.7 ) (0.2 ) (0.1 ) 5.1 0.1 Equity in net income of nonconsolidated affiliates — (1.9 ) (0.4 ) — (2.3 ) Equity in net income of consolidated affiliates (112.3 ) (16.5 ) — 128.8 — Management fees (38.4 ) 28.8 9.6 — — Income from continuing operations before income tax (benefit) expense 67.5 136.6 60.4 (128.8 ) 135.7 Provision for income tax (benefit) expense (16.8 ) 36.8 10.0 — 30.0 Income from continuing operations 84.3 99.8 50.4 (128.8 ) 105.7 Loss from discontinued operations, net of tax (0.5 ) — — — (0.5 ) Net and comprehensive income 83.8 99.8 50.4 (128.8 ) 105.2 Less: Net and comprehensive income attributable to noncontrolling interests — — (21.4 ) — (21.4 ) Net and comprehensive income attributable to Encompass Health $ 83.8 $ 99.8 $ 29.0 $ (128.8 ) $ 83.8 As of March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 34.7 $ 3.5 $ 17.9 $ — $ 56.1 Restricted cash — — 59.0 — 59.0 Accounts receivable — 292.5 208.1 — 500.6 Other current assets 69.3 32.2 67.6 (102.1 ) 67.0 Total current assets 104.0 328.2 352.6 (102.1 ) 682.7 Property and equipment, net 126.0 1,090.6 519.6 — 1,736.2 Operating lease right-of-use assets 15.2 176.6 122.7 (29.6 ) 284.9 Goodwill — 912.2 1,199.4 — 2,111.6 Intangible assets, net 20.5 93.4 321.5 — 435.4 Deferred income tax assets 38.5 28.9 — (26.9 ) 40.5 Other long-term assets 50.7 95.4 146.4 — 292.5 Intercompany notes receivable 540.4 — — (540.4 ) — Intercompany receivable and investments in consolidated affiliates 2,957.6 546.6 — (3,504.2 ) — Total assets $ 3,852.9 $ 3,271.9 $ 2,662.2 $ (4,203.2 ) $ 5,583.8 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 35.4 $ 8.5 $ 10.9 $ (17.5 ) $ 37.3 Current operating lease liabilities 2.5 25.6 27.5 (7.3 ) 48.3 Accounts payable 9.5 48.7 36.5 — 94.7 Accrued expenses and other current liabilities 262.2 86.4 323.9 (84.6 ) 587.9 Total current liabilities 309.6 169.2 398.8 (109.4 ) 768.2 Long-term debt, net of current portion 2,176.8 292.1 52.9 — 2,521.8 Long-term operating lease liabilities 12.9 155.0 99.4 (22.3 ) 245.0 Intercompany notes payable — — 540.4 (540.4 ) — Other long-term liabilities 39.3 10.8 136.0 (26.8 ) 159.3 Intercompany payable — — 64.6 (64.6 ) — 2,538.6 627.1 1,292.1 (763.5 ) 3,694.3 Commitments and contingencies Redeemable noncontrolling interests — — 273.0 — 273.0 Shareholders’ equity: Encompass Health shareholders’ equity 1,314.3 2,644.8 794.9 (3,439.7 ) 1,314.3 Noncontrolling interests — — 302.2 — 302.2 Total shareholders’ equity 1,314.3 2,644.8 1,097.1 (3,439.7 ) 1,616.5 Total liabilities and shareholders’ equity $ 3,852.9 $ 3,271.9 $ 2,662.2 $ (4,203.2 ) $ 5,583.8 As of December 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.5 $ 3.0 $ 24.7 $ — $ 69.2 Restricted cash — — 59.0 — 59.0 Accounts receivable — 270.7 197.0 — 467.7 Other current assets 36.3 17.6 31.1 (18.8 ) 66.2 Total current assets 77.8 291.3 311.8 (18.8 ) 662.1 Property and equipment, net 123.9 1,041.5 469.4 — 1,634.8 Goodwill — 912.2 1,188.6 — 2,100.8 Intangible assets, net 21.4 96.5 325.5 — 443.4 Deferred income tax assets 47.9 28.9 — (33.9 ) 42.9 Other long-term assets 47.9 101.3 141.8 — 291.0 Intercompany notes receivable 535.3 — — (535.3 ) — Intercompany receivable and investments in consolidated affiliates 2,904.4 456.8 — (3,361.2 ) — Total assets $ 3,758.6 $ 2,928.5 $ 2,437.1 $ (3,949.2 ) $ 5,175.0 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 35.0 $ 7.6 $ 10.7 $ (17.5 ) $ 35.8 Accounts payable 8.9 46.4 34.7 — 90.0 Accrued expenses and other current liabilities 211.8 76.4 259.8 (1.3 ) 546.7 Total current liabilities 255.7 130.4 305.2 (18.8 ) 672.5 Long-term debt, net of current portion 2,188.7 262.1 27.8 — 2,478.6 Intercompany notes payable — — 535.3 (535.3 ) — Other long-term liabilities 37.5 17.1 184.4 (33.8 ) 205.2 Intercompany payable — — 53.3 (53.3 ) — 2,481.9 409.6 1,106.0 (641.2 ) 3,356.3 Commitments and contingencies Redeemable noncontrolling interests — — 261.7 — 261.7 Shareholders’ equity: Encompass Health shareholders’ equity 1,276.7 2,518.9 789.1 (3,308.0 ) 1,276.7 Noncontrolling interests — — 280.3 — 280.3 Total shareholders’ equity 1,276.7 2,518.9 1,069.4 (3,308.0 ) 1,557.0 Total liabilities and shareholders’ equity $ 3,758.6 $ 2,928.5 $ 2,437.1 $ (3,949.2 ) $ 5,175.0 Three Months Ended March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net cash provided by operating activities $ 18.6 $ 89.6 $ 51.7 $ — $ 159.9 Cash flows from investing activities: Purchases of property and equipment (6.8 ) (32.5 ) (33.0 ) — (72.3 ) Acquisitions of businesses, net of cash acquired — — (13.7 ) — (13.7 ) Funding of intercompany note receivable (8.0 ) — — 8.0 — Proceeds from repayment of intercompany note receivable 5.0 — — (5.0 ) — Other, net (4.0 ) (0.1 ) (1.4 ) — (5.5 ) Net cash used in investing activities (13.8 ) (32.6 ) (48.1 ) 3.0 (91.5 ) Cash flows from financing activities: Principal borrowings on intercompany note payable — — 8.0 (8.0 ) — Principal payments on intercompany note payable — — (5.0 ) 5.0 — Borrowings on revolving credit facility 25.0 — — — 25.0 Payments on revolving credit facility (30.0 ) — — — (30.0 ) Dividends paid on common stock (28.2 ) — (0.1 ) — (28.3 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (19.5 ) — (19.5 ) Taxes paid on behalf of employees for shares withheld (14.7 ) — (1.2 ) — (15.9 ) Other, net (14.7 ) (2.1 ) 3.8 — (13.0 ) Change in intercompany advances 51.0 (54.4 ) 3.4 — — Net cash used in financing activities (11.6 ) (56.5 ) (10.6 ) (3.0 ) (81.7 ) (Decrease) increase in cash, cash equivalents, and restricted cash (6.8 ) 0.5 (7.0 ) — (13.3 ) Cash, cash equivalents, and restricted cash at beginning of period 41.5 3.0 89.0 — 133.5 Cash, cash equivalents, and restricted cash at end of period $ 34.7 $ 3.5 $ 82.0 $ — $ 120.2 Reconciliation of Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents at beginning of period $ 41.5 $ 3.0 $ 24.7 $ — $ 69.2 Restricted cash at beginning of period — — 59.0 — 59.0 Restricted cash included in other long term assets at beginning of period — — 5.3 — 5.3 Cash, cash equivalents, and restricted cash at beginning of period $ 41.5 $ 3.0 $ 89.0 $ — $ 133.5 Cash and cash equivalents at end of period $ 34.7 $ 3.5 $ 17.9 $ — $ 56.1 Restricted cash at end of period — — 59.0 — 59.0 Restricted cash included in other long-term assets at end of period — — 5.1 — 5.1 Cash, cash equivalents, and restricted cash at end of period $ 34.7 $ 3.5 $ 82.0 $ — $ 120.2 Three Months Ended March 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net cash provided by operating activities $ 10.2 $ 114.3 $ 91.8 $ — $ 216.3 Cash flows from investing activities: Purchases of property and equipment (12.3 ) (31.5 ) (16.1 ) — (59.9 ) Acquisitions of businesses, net of cash acquired — — (0.6 ) — (0.6 ) Proceeds from repayment of intercompany note receivable 22.0 — — (22.0 ) — Other, net (5.1 ) (0.1 ) 5.1 — (0.1 ) Net cash provided by (used in) investing activities 4.6 (31.6 ) (11.6 ) (22.0 ) (60.6 ) Cash flows from financing activities: Principal payments on intercompany note payable — — (22.0 ) 22.0 — Borrowings on revolving credit facility 95.0 — — — 95.0 Payments on revolving credit facility (95.0 ) — — — (95.0 ) Dividends paid on common stock (25.3 ) — (0.1 ) — (25.4 ) Purchase of equity interests in consolidated affiliates (65.1 ) — — — (65.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (15.4 ) — (15.4 ) Taxes paid on behalf of employees for shares withheld (7.4 ) — (0.9 ) — (8.3 ) Other, net 2.3 (2.0 ) (2.8 ) — (2.5 ) Change in intercompany advances 115.4 (80.7 ) (34.7 ) — — Net cash provided by (used in) financing activities 19.9 (82.7 ) (75.9 ) 22.0 (116.7 ) Increase in cash, cash equivalents, and restricted cash 34.7 — 4.3 — 39.0 Cash, cash equivalents, and restricted cash at beginning of period 34.3 3.0 79.5 — 116.8 Cash, cash equivalents, and restricted cash at end of period $ 69.0 $ 3.0 $ 83.8 $ — $ 155.8 Reconciliation of Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents at beginning of period $ 34.3 $ 3.0 $ 17.1 $ — $ 54.4 Restricted cash at beginning of period — — 62.4 — 62.4 Cash, cash equivalents, and restricted cash at beginning of period $ 34.3 $ 3.0 $ 79.5 $ — $ 116.8 Cash and cash equivalents at end of period $ 69.0 $ 3.0 $ 14.4 $ — $ 86.4 Restricted cash at end of period — — 69.4 — 69.4 Cash, cash equivalents, and restricted cash at end of period $ 69.0 $ 3.0 $ 83.8 $ — $ 155.8

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Operating Revenues	Net Operating Revenues — Our Net operating revenues disaggregated by payor source and segment are as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Consolidated Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, 2019 2018 2019 2018 2019 2018 Medicare $ 638.9 $ 624.5 $ 214.8 $ 176.9 $ 853.7 $ 801.4 Medicare Advantage 85.2 72.5 25.5 20.0 110.7 92.5 Managed care 83.5 85.0 8.4 7.6 91.9 92.6 Medicaid 26.2 24.7 4.3 0.5 30.5 25.2 Other third-party payors 10.0 12.0 — — 10.0 12.0 Workers’ compensation 8.2 7.4 0.2 0.1 8.4 7.5 Patients 6.1 4.4 0.4 0.4 6.5 4.8 Other income 12.0 9.8 0.3 0.2 12.3 10.0 Total $ 870.1 $ 840.3 $ 253.9 $ 205.7 $ 1,124.0 $ 1,046.0 See Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2018 Form 10-K for our policy related to Net operating revenues .
Leases	Leases— We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. We do not account for lease and nonlease components separately for purposes of establishing right-of-use assets and lease liabilities. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements — In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” and has subsequently issued supplemental and/or clarifying ASUs (collectively “ASC 842”), in order to increase transparency and comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. We adopted ASC 842 using the modified retrospective approach and applied the transition provisions with an effective date as of January 1, 2019 for leases that existed on that date. Prior period results continue to be presented under ASC 840 based on the accounting originally in effect for such periods. ASC 842 provides optional practical expedients in transition. We elected the ‘package of practical expedients,’ which permits us to not reassess under ASC 842 our prior conclusions about lease identification, lease classification and initial direct costs, and the practical expedient to not reassess certain land easements. We did not elect the use-of-hindsight practical expedient during the transition to ASC 842. The adoption of ASC 842 resulted in the addition of approximately $349 million in assets and $347 million in liabilities to our condensed consolidated balance sheet as of January 1, 2019, with the remaining $2 million being recorded as an adjustment to Capital in excess of par value . The adoption of ASC 842 also resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of cash flows arising from leases. See the “Leases” section of this note and Note 4, Leases , for additional information about our leases. Recent Accounting Pronouncements Not Yet Adopted — In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326),” which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance is effective for us beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted beginning January 1, 2019. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The update helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement), by providing guidance in determining when the arrangement includes a software license. It requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The new guidance is effective for us beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Concentration of Net Operating Revenues by Payor	Our Net operating revenues disaggregated by payor source and segment are as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Consolidated Three Months Ended March 31, Three Months Ended March 31, Three Months Ended March 31, 2019 2018 2019 2018 2019 2018 Medicare $ 638.9 $ 624.5 $ 214.8 $ 176.9 $ 853.7 $ 801.4 Medicare Advantage 85.2 72.5 25.5 20.0 110.7 92.5 Managed care 83.5 85.0 8.4 7.6 91.9 92.6 Medicaid 26.2 24.7 4.3 0.5 30.5 25.2 Other third-party payors 10.0 12.0 — — 10.0 12.0 Workers’ compensation 8.2 7.4 0.2 0.1 8.4 7.5 Patients 6.1 4.4 0.4 0.4 6.5 4.8 Other income 12.0 9.8 0.3 0.2 12.3 10.0 Total $ 870.1 $ 840.3 $ 253.9 $ 205.7 $ 1,124.0 $ 1,046.0
Revision of Previously Issued Financial Statements [Table Text Block]	For additional information on this revision, see Note 1, Summary of Significant Accounting Policies , “Revision of Previously Issued Financial Statements” to the consolidated financial statements accompanying the 2018 Form 10-K. As Reported Adjustment As Revised For the Three Months Ended March 31, 2018 (In Millions) Fair value adjustments to redeemable noncontrolling interests $ (40.5 ) $ (1.7 ) $ (42.2 ) Capital in excess of par value 2,731.6 (45.7 ) 2,685.9 Accumulated deficit (1,108.5 ) 14.8 (1,093.7 ) Total shareholders’ equity 1,440.8 (30.9 ) 1,409.9

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date	The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Identifiable intangible assets: Noncompete agreements (useful lives of 5 years) $ 0.2 Certificates of need (useful lives of 10 years) 2.0 License (useful life of 10 years) 0.8 Goodwill 10.8 Other assets acquired 0.2 Total assets acquired 14.0 Liabilities assumed: Accrued payroll (0.1 ) Other current liabilities (0.1 ) Other long-term liabilities (0.1 ) Total liabilities assumed (0.3 ) Net assets acquired $ 13.7
Schedule of Noncash or Part Noncash Acquisitions	Information regarding the net cash paid for the other home health and hospice acquisitions during each period presented is as follows (in millions): Three Months Ended March 31, 2019 2018 Fair value of assets acquired $ 3.2 $ 0.1 Goodwill 10.8 0.5 Fair value of liabilities assumed (0.3 ) — Net cash paid for acquisitions $ 13.7 $ 0.6
Summary of Actual and Pro Forma Results of Operations for Acquisitions	The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2018 (in millions): Net Operating Revenues Net Income Attributable to Encompass Health Acquired entities only: Actual from acquisition date to March 31, 2019 Home Health and Hospice $ 1.0 $ (0.1 ) Combined entity: Supplemental pro forma from 01/01/2019-03/31/2019 1,126.0 102.5 Combined entity: Supplemental pro forma from 01/01/2018-03/31/2018 1,048.4 84.0

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of carrying amounts and classifications of VIE's assets and liabilities	The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions): March 31, 2019 December 31, 2018 Assets Current assets: Cash and cash equivalents $ 0.7 $ 0.3 Accounts receivable 31.0 31.0 Other current assets 5.9 4.9 Total current assets 37.6 36.2 Property and equipment, net 121.2 111.5 Operating lease right-of-use assets 7.2 — Goodwill 15.9 15.9 Intangible assets, net 4.0 4.3 Other long-term assets 30.3 29.6 Total assets $ 216.2 $ 197.5 Liabilities Current liabilities: Current portion of long-term debt $ 0.7 $ 0.6 Current operating lease liabilities 1.4 — Accounts payable 5.6 5.2 Accrued expenses and other current liabilities 37.7 45.0 Total current liabilities 45.4 50.8 Long-term debt, net of current portion 11.1 — Long-term operating lease liabilities 5.7 — Total liabilities $ 62.2 $ 50.8

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Components of Lease Costs	The components of lease costs are as follows (in millions): Three Months Ended March 31, 2019 Operating lease cost $ 17.5 Finance lease cost: Amortization of right-of-use assets 11.9 Interest on lease liabilities 8.1 Total finance lease cost 20.0 Short-term and variable lease cost 0.3 Sublease income (0.8 ) Total lease cost $ 37.0
Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]	Supplemental condensed consolidated balance sheet information related to leases is as follows (in millions): Classification As of March 31, 2019 Assets Operating lease Operating lease right-of-use assets $ 284.9 Finance lease (1) Property and equipment, net 344.0 Total leased assets $ 628.9 Liabilities Current liabilities: Operating lease Current operating lease liabilities $ 48.3 Finance lease Current portion of long-term debt 18.2 Noncurrent liabilities: Operating lease Long-term operating lease liabilities 245.0 Finance lease Long-term debt, net of current portion 381.9 Total leased liabilities $ 693.4 (1) Finance lease assets are recorded net of accumulated amortization of $95.6 million as of March 31, 2019. Classification Assets Operating lease Operating lease right-of-use assets Finance lease (1) us-gaap:PropertyPlantAndEquipmentNet Total leased assets Liabilities Current liabilities: Operating lease Current operating lease liabilities Finance lease us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent Noncurrent liabilities: Operating lease Long-term operating lease liabilities Finance lease us-gaap:LongTermDebtAndCapitalLeaseObligations Total leased liabilities
Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]	As of March 31, 2019 Weighted Average Remaining Lease Term Operating lease 8.6 years Finance lease 13.5 years Weighted Average Discount Rate Operating lease 6.3 % Finance lease 8.2 %
Maturities of Finance Lease Liabilities [Table Text Block]	Maturities of lease liabilities as of March 31, 2019 are as follows (in millions): Operating Leases Finance Leases April 1 through December 31, 2019 $ 48.1 $ 37.8 2020 58.6 49.9 2021 51.0 48.0 2022 40.8 57.6 2023 35.4 43.7 2024 31.3 58.1 2025 and Thereafter 129.7 391.4 Total lease payments 394.9 686.5 Less: Interest portion (101.6 ) (286.4 ) Total lease liabilities $ 293.3 $ 400.1
Maturities of Operating Lease Liabilities [Table Text Block]	Maturities of lease liabilities as of March 31, 2019 are as follows (in millions): Operating Leases Finance Leases April 1 through December 31, 2019 $ 48.1 $ 37.8 2020 58.6 49.9 2021 51.0 48.0 2022 40.8 57.6 2023 35.4 43.7 2024 31.3 58.1 2025 and Thereafter 129.7 391.4 Total lease payments 394.9 686.5 Less: Interest portion (101.6 ) (286.4 ) Total lease liabilities $ 293.3 $ 400.1
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments at December 31, 2018, for those leases having an initial or remaining noncancelable lease term in excess of one year, are as follows (in millions): Year Ending December 31, Operating Leases Capital Lease Obligations 2019 $ 71.4 $ 36.2 2020 65.8 32.3 2021 54.3 30.3 2022 41.0 28.7 2023 35.3 28.0 2024 and Thereafter 148.2 299.7 $ 416.0 455.2 Less: Interest portion (191.4 ) Obligations under capital leases $ 263.8
Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to our leases is as follows (in millions): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 17.2 Operating cash flows from finance leases 8.0 Financing cash flows from finance leases 2.8 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 5.5 Finance leases 3.1

Investments in and Advances t_2

Investments in and Advances to Nonconsolidated Affiliates (Tables)	3 Months Ended
	Mar. 31, 2019
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Schedule of Combined Results of Operations of Equity Method Affiliates	The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended March 31, 2019 2018 Net operating revenues $ 11.6 $ 11.0 Operating expenses (6.8 ) (7.6 ) Income from continuing operations, net of tax 4.9 3.4 Net income 4.9 3.4

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	3 Months Ended
	Mar. 31, 2019
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	The following is a summary of the activity related to our Redeemable noncontrolling interests during the three months ended March 31, 2019 and 2018 (in millions): Three Months Ended March 31, 2019 2018 Balance at beginning of period $ 261.7 $ 220.9 Net income attributable to noncontrolling interests 4.0 2.8 Distributions declared (1.8 ) (2.2 ) Reclassification to noncontrolling interests (11.2 ) — Purchase of redeemable noncontrolling interests — (65.1 ) Change in fair value 20.3 42.2 Balance at end of period $ 273.0 $ 198.6
Reconciliation of Noncontrolling Interests	The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of comprehensive income for the three months ended March 31, 2019 and 2018 (in millions): Three Months Ended March 31, 2019 2018 Net income attributable to nonredeemable noncontrolling interests $ 18.9 $ 18.6 Net income attributable to redeemable noncontrolling interests 4.0 2.8 Net income attributable to noncontrolling interests $ 22.9 $ 21.4

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis	Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of March 31, 2019 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other long-term assets: Restricted marketable securities $ 63.6 $ 6.7 $ 56.9 $ — M Redeemable noncontrolling interests 273.0 — — 273.0 I As of December 31, 2018 Other long-term assets: Restricted marketable securities $ 62.0 $ 6.4 $ 55.6 $ — M Redeemable noncontrolling interests 261.7 — — 261.7 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments	The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of March 31, 2019 As of December 31, 2018 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 25.0 $ 25.0 $ 30.0 $ 30.0 Term loan facilities 276.4 277.5 280.1 281.3 5.125% Senior Notes due 2023 296.8 305.3 296.6 298.5 5.75% Senior Notes due 2024 1,194.8 1,221.0 1,194.7 1,200.0 5.75% Senior Notes due 2025 345.2 357.9 345.0 339.5 Other notes payable 20.8 20.8 104.2 104.2 Financial commitments: Letters of credit — 39.1 — 37.4

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Common Share	The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended March 31, 2019 2018 Basic: Numerator: Income from continuing operations $ 125.7 $ 105.7 Less: Net income attributable to noncontrolling interests included in continuing operations (22.9 ) (21.4 ) Less: Income allocated to participating securities (0.4 ) (0.3 ) Income from continuing operations attributable to Encompass Health common shareholders 102.4 84.0 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders (0.5 ) (0.5 ) Net income attributable to Encompass Health common shareholders $ 101.9 $ 83.5 Denominator: Basic weighted average common shares outstanding 98.4 97.8 Basic earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.05 $ 0.86 Discontinued operations (0.01 ) (0.01 ) Net income $ 1.04 $ 0.85 Diluted: Numerator: Income from continuing operations $ 125.7 $ 105.7 Less: Net income attributable to noncontrolling interests included in continuing operations (22.9 ) (21.4 ) Income from continuing operations attributable to Encompass Health common shareholders 102.8 84.3 Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders (0.5 ) (0.5 ) Net income attributable to Encompass Health common shareholders $ 102.3 $ 83.8 Denominator: Diluted weighted average common shares outstanding 99.7 99.4 Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.04 $ 0.85 Discontinued operations (0.01 ) (0.01 ) Net income $ 1.03 $ 0.84
Reconciliation of Weighted Average Number of Shares Outstanding	The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended March 31, 2019 2018 Basic weighted average common shares outstanding 98.4 97.8 Restricted stock awards, dilutive stock options, and restricted stock units 1.3 1.6 Diluted weighted average common shares outstanding 99.7 99.4

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended March 31, Three Months Ended March 31, 2019 2018 2019 2018 Net operating revenues $ 870.1 $ 840.3 $ 253.9 $ 205.7 Operating expenses: Inpatient rehabilitation: Salaries and benefits 445.0 424.2 — — Other operating expenses 127.6 122.9 — — Supplies 35.6 35.9 — — Occupancy costs 15.8 15.5 — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — 116.5 98.6 Support and overhead costs — — 88.8 72.0 624.0 598.5 205.3 170.6 Other income (2.8 ) (0.5 ) — — Equity in net income of nonconsolidated affiliates (2.1 ) (2.0 ) (0.4 ) (0.3 ) Noncontrolling interests 21.0 20.5 2.7 1.9 Segment Adjusted EBITDA $ 230.0 $ 223.8 $ 46.3 $ 33.5 Capital expenditures $ 70.4 $ 62.2 $ 4.5 $ 1.7
Reconciliation of Assets from Segment to Consolidated	March 31, 2019 December 31, 2018 Total assets for reportable segments $ 5,617.3 $ 5,215.5 Reclassification of deferred income tax liabilities to net deferred income tax assets (33.5 ) (40.5 ) Total consolidated assets $ 5,583.8 $ 5,175.0 Inpatient Rehabilitation Home Health and Hospice Encompass Health Consolidated As of March 31, 2019 Total assets $ 4,250.5 $ 1,366.8 $ 5,583.8 Investments in and advances to nonconsolidated affiliates 9.4 3.1 12.5 As of December 31, 2018 Total assets $ 3,900.9 $ 1,314.6 $ 5,175.0 Investments in and advances to nonconsolidated affiliates 9.5 2.7 12.2
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense	Segment reconciliations (in millions): Three Months Ended March 31, 2019 2018 Total segment Adjusted EBITDA $ 276.3 $ 257.3 General and administrative expenses (53.4 ) (61.1 ) Depreciation and amortization (52.5 ) (45.9 ) Loss on disposal of assets (1.1 ) (0.8 ) Interest expense and amortization of debt discounts and fees (37.2 ) (35.6 ) Net income attributable to noncontrolling interests 22.9 21.4 SARs mark-to-market impact on noncontrolling interests 0.8 1.0 Change in fair market value of equity securities 0.9 (0.6 ) Payroll taxes on SARs exercise (0.2 ) — Income from continuing operations before income tax expense $ 156.5 $ 135.7
Reconciliation of Revenue from Segments to Consolidated	Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended March 31, 2019 2018 Inpatient rehabilitation: Inpatient $ 847.6 $ 817.1 Outpatient and other 22.5 23.2 Total inpatient rehabilitation 870.1 840.3 Home health and hospice: Home health 219.5 185.3 Hospice 34.4 20.4 Total home health and hospice 253.9 205.7 Total net operating revenues $ 1,124.0 $ 1,046.0

Condensed Consolidating Finan_2

Condensed Consolidating Financial Information (Tables)	3 Months Ended
	Mar. 31, 2019
Condensed Financial Information Disclosure [Abstract]
Condensed Consolidating Statement of Comprehensive Income	Three Months Ended March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net operating revenues $ 5.1 $ 606.5 $ 546.0 $ (33.6 ) $ 1,124.0 Operating expenses: Salaries and benefits 15.9 288.9 321.1 (5.1 ) 620.8 Other operating expenses 10.3 84.7 67.6 (12.5 ) 150.1 Occupancy costs 0.5 24.9 10.2 (16.0 ) 19.6 Supplies — 24.0 16.1 — 40.1 General and administrative expenses 39.9 — 13.5 — 53.4 Depreciation and amortization 5.0 26.3 21.2 — 52.5 Total operating expenses 71.6 448.8 449.7 (33.6 ) 936.5 Interest expense and amortization of debt discounts and fees 30.1 6.2 7.7 (6.8 ) 37.2 Other income (7.7 ) (0.3 ) (2.5 ) 6.8 (3.7 ) Equity in net income of nonconsolidated affiliates — (2.1 ) (0.4 ) — (2.5 ) Equity in net income of consolidated affiliates (130.2 ) (17.0 ) — 147.2 — Management fees (39.8 ) 29.5 10.3 — — Income from continuing operations before income tax (benefit) expense 81.1 141.4 81.2 (147.2 ) 156.5 Provision for income tax (benefit) expense (21.7 ) 37.8 14.7 — 30.8 Income from continuing operations 102.8 103.6 66.5 (147.2 ) 125.7 Loss from discontinued operations, net of tax (0.5 ) — — — (0.5 ) Net and comprehensive income 102.3 103.6 66.5 (147.2 ) 125.2 Less: Net and comprehensive income attributable to noncontrolling interests — — (22.9 ) — (22.9 ) Net and comprehensive income attributable to Encompass Health $ 102.3 $ 103.6 $ 43.6 $ (147.2 ) $ 102.3 Three Months Ended March 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net operating revenues $ 5.4 $ 594.6 $ 478.6 $ (32.6 ) $ 1,046.0 Operating expenses: Salaries and benefits 13.2 282.4 280.0 (5.4 ) 570.2 Other operating expenses 8.4 84.6 60.6 (12.4 ) 141.2 Occupancy costs 0.5 23.8 9.1 (14.8 ) 18.6 Supplies — 24.7 15.2 — 39.9 General and administrative expenses 39.4 — 21.7 — 61.1 Depreciation and amortization 2.0 26.6 17.3 — 45.9 Total operating expenses 63.5 442.1 403.9 (32.6 ) 876.9 Interest expense and amortization of debt discounts and fees 29.8 5.7 5.2 (5.1 ) 35.6 Other (income) loss (4.7 ) (0.2 ) (0.1 ) 5.1 0.1 Equity in net income of nonconsolidated affiliates — (1.9 ) (0.4 ) — (2.3 ) Equity in net income of consolidated affiliates (112.3 ) (16.5 ) — 128.8 — Management fees (38.4 ) 28.8 9.6 — — Income from continuing operations before income tax (benefit) expense 67.5 136.6 60.4 (128.8 ) 135.7 Provision for income tax (benefit) expense (16.8 ) 36.8 10.0 — 30.0 Income from continuing operations 84.3 99.8 50.4 (128.8 ) 105.7 Loss from discontinued operations, net of tax (0.5 ) — — — (0.5 ) Net and comprehensive income 83.8 99.8 50.4 (128.8 ) 105.2 Less: Net and comprehensive income attributable to noncontrolling interests — — (21.4 ) — (21.4 ) Net and comprehensive income attributable to Encompass Health $ 83.8 $ 99.8 $ 29.0 $ (128.8 ) $ 83.8
Condensed Consolidating Balance Sheet	As of March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 34.7 $ 3.5 $ 17.9 $ — $ 56.1 Restricted cash — — 59.0 — 59.0 Accounts receivable — 292.5 208.1 — 500.6 Other current assets 69.3 32.2 67.6 (102.1 ) 67.0 Total current assets 104.0 328.2 352.6 (102.1 ) 682.7 Property and equipment, net 126.0 1,090.6 519.6 — 1,736.2 Operating lease right-of-use assets 15.2 176.6 122.7 (29.6 ) 284.9 Goodwill — 912.2 1,199.4 — 2,111.6 Intangible assets, net 20.5 93.4 321.5 — 435.4 Deferred income tax assets 38.5 28.9 — (26.9 ) 40.5 Other long-term assets 50.7 95.4 146.4 — 292.5 Intercompany notes receivable 540.4 — — (540.4 ) — Intercompany receivable and investments in consolidated affiliates 2,957.6 546.6 — (3,504.2 ) — Total assets $ 3,852.9 $ 3,271.9 $ 2,662.2 $ (4,203.2 ) $ 5,583.8 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 35.4 $ 8.5 $ 10.9 $ (17.5 ) $ 37.3 Current operating lease liabilities 2.5 25.6 27.5 (7.3 ) 48.3 Accounts payable 9.5 48.7 36.5 — 94.7 Accrued expenses and other current liabilities 262.2 86.4 323.9 (84.6 ) 587.9 Total current liabilities 309.6 169.2 398.8 (109.4 ) 768.2 Long-term debt, net of current portion 2,176.8 292.1 52.9 — 2,521.8 Long-term operating lease liabilities 12.9 155.0 99.4 (22.3 ) 245.0 Intercompany notes payable — — 540.4 (540.4 ) — Other long-term liabilities 39.3 10.8 136.0 (26.8 ) 159.3 Intercompany payable — — 64.6 (64.6 ) — 2,538.6 627.1 1,292.1 (763.5 ) 3,694.3 Commitments and contingencies Redeemable noncontrolling interests — — 273.0 — 273.0 Shareholders’ equity: Encompass Health shareholders’ equity 1,314.3 2,644.8 794.9 (3,439.7 ) 1,314.3 Noncontrolling interests — — 302.2 — 302.2 Total shareholders’ equity 1,314.3 2,644.8 1,097.1 (3,439.7 ) 1,616.5 Total liabilities and shareholders’ equity $ 3,852.9 $ 3,271.9 $ 2,662.2 $ (4,203.2 ) $ 5,583.8 As of December 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 41.5 $ 3.0 $ 24.7 $ — $ 69.2 Restricted cash — — 59.0 — 59.0 Accounts receivable — 270.7 197.0 — 467.7 Other current assets 36.3 17.6 31.1 (18.8 ) 66.2 Total current assets 77.8 291.3 311.8 (18.8 ) 662.1 Property and equipment, net 123.9 1,041.5 469.4 — 1,634.8 Goodwill — 912.2 1,188.6 — 2,100.8 Intangible assets, net 21.4 96.5 325.5 — 443.4 Deferred income tax assets 47.9 28.9 — (33.9 ) 42.9 Other long-term assets 47.9 101.3 141.8 — 291.0 Intercompany notes receivable 535.3 — — (535.3 ) — Intercompany receivable and investments in consolidated affiliates 2,904.4 456.8 — (3,361.2 ) — Total assets $ 3,758.6 $ 2,928.5 $ 2,437.1 $ (3,949.2 ) $ 5,175.0 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 35.0 $ 7.6 $ 10.7 $ (17.5 ) $ 35.8 Accounts payable 8.9 46.4 34.7 — 90.0 Accrued expenses and other current liabilities 211.8 76.4 259.8 (1.3 ) 546.7 Total current liabilities 255.7 130.4 305.2 (18.8 ) 672.5 Long-term debt, net of current portion 2,188.7 262.1 27.8 — 2,478.6 Intercompany notes payable — — 535.3 (535.3 ) — Other long-term liabilities 37.5 17.1 184.4 (33.8 ) 205.2 Intercompany payable — — 53.3 (53.3 ) — 2,481.9 409.6 1,106.0 (641.2 ) 3,356.3 Commitments and contingencies Redeemable noncontrolling interests — — 261.7 — 261.7 Shareholders’ equity: Encompass Health shareholders’ equity 1,276.7 2,518.9 789.1 (3,308.0 ) 1,276.7 Noncontrolling interests — — 280.3 — 280.3 Total shareholders’ equity 1,276.7 2,518.9 1,069.4 (3,308.0 ) 1,557.0 Total liabilities and shareholders’ equity $ 3,758.6 $ 2,928.5 $ 2,437.1 $ (3,949.2 ) $ 5,175.0
Condensed Consolidating Statement of Cash Flows	Three Months Ended March 31, 2019 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net cash provided by operating activities $ 18.6 $ 89.6 $ 51.7 $ — $ 159.9 Cash flows from investing activities: Purchases of property and equipment (6.8 ) (32.5 ) (33.0 ) — (72.3 ) Acquisitions of businesses, net of cash acquired — — (13.7 ) — (13.7 ) Funding of intercompany note receivable (8.0 ) — — 8.0 — Proceeds from repayment of intercompany note receivable 5.0 — — (5.0 ) — Other, net (4.0 ) (0.1 ) (1.4 ) — (5.5 ) Net cash used in investing activities (13.8 ) (32.6 ) (48.1 ) 3.0 (91.5 ) Cash flows from financing activities: Principal borrowings on intercompany note payable — — 8.0 (8.0 ) — Principal payments on intercompany note payable — — (5.0 ) 5.0 — Borrowings on revolving credit facility 25.0 — — — 25.0 Payments on revolving credit facility (30.0 ) — — — (30.0 ) Dividends paid on common stock (28.2 ) — (0.1 ) — (28.3 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (19.5 ) — (19.5 ) Taxes paid on behalf of employees for shares withheld (14.7 ) — (1.2 ) — (15.9 ) Other, net (14.7 ) (2.1 ) 3.8 — (13.0 ) Change in intercompany advances 51.0 (54.4 ) 3.4 — — Net cash used in financing activities (11.6 ) (56.5 ) (10.6 ) (3.0 ) (81.7 ) (Decrease) increase in cash, cash equivalents, and restricted cash (6.8 ) 0.5 (7.0 ) — (13.3 ) Cash, cash equivalents, and restricted cash at beginning of period 41.5 3.0 89.0 — 133.5 Cash, cash equivalents, and restricted cash at end of period $ 34.7 $ 3.5 $ 82.0 $ — $ 120.2 Reconciliation of Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents at beginning of period $ 41.5 $ 3.0 $ 24.7 $ — $ 69.2 Restricted cash at beginning of period — — 59.0 — 59.0 Restricted cash included in other long term assets at beginning of period — — 5.3 — 5.3 Cash, cash equivalents, and restricted cash at beginning of period $ 41.5 $ 3.0 $ 89.0 $ — $ 133.5 Cash and cash equivalents at end of period $ 34.7 $ 3.5 $ 17.9 $ — $ 56.1 Restricted cash at end of period — — 59.0 — 59.0 Restricted cash included in other long-term assets at end of period — — 5.1 — 5.1 Cash, cash equivalents, and restricted cash at end of period $ 34.7 $ 3.5 $ 82.0 $ — $ 120.2 Three Months Ended March 31, 2018 Encompass Health Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries Encompass Health Consolidated (In Millions) Net cash provided by operating activities $ 10.2 $ 114.3 $ 91.8 $ — $ 216.3 Cash flows from investing activities: Purchases of property and equipment (12.3 ) (31.5 ) (16.1 ) — (59.9 ) Acquisitions of businesses, net of cash acquired — — (0.6 ) — (0.6 ) Proceeds from repayment of intercompany note receivable 22.0 — — (22.0 ) — Other, net (5.1 ) (0.1 ) 5.1 — (0.1 ) Net cash provided by (used in) investing activities 4.6 (31.6 ) (11.6 ) (22.0 ) (60.6 ) Cash flows from financing activities: Principal payments on intercompany note payable — — (22.0 ) 22.0 — Borrowings on revolving credit facility 95.0 — — — 95.0 Payments on revolving credit facility (95.0 ) — — — (95.0 ) Dividends paid on common stock (25.3 ) — (0.1 ) — (25.4 ) Purchase of equity interests in consolidated affiliates (65.1 ) — — — (65.1 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (15.4 ) — (15.4 ) Taxes paid on behalf of employees for shares withheld (7.4 ) — (0.9 ) — (8.3 ) Other, net 2.3 (2.0 ) (2.8 ) — (2.5 ) Change in intercompany advances 115.4 (80.7 ) (34.7 ) — — Net cash provided by (used in) financing activities 19.9 (82.7 ) (75.9 ) 22.0 (116.7 ) Increase in cash, cash equivalents, and restricted cash 34.7 — 4.3 — 39.0 Cash, cash equivalents, and restricted cash at beginning of period 34.3 3.0 79.5 — 116.8 Cash, cash equivalents, and restricted cash at end of period $ 69.0 $ 3.0 $ 83.8 $ — $ 155.8 Reconciliation of Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents at beginning of period $ 34.3 $ 3.0 $ 17.1 $ — $ 54.4 Restricted cash at beginning of period — — 62.4 — 62.4 Cash, cash equivalents, and restricted cash at beginning of period $ 34.3 $ 3.0 $ 79.5 $ — $ 116.8 Cash and cash equivalents at end of period $ 69.0 $ 3.0 $ 14.4 $ — $ 86.4 Restricted cash at end of period — — 69.4 — 69.4 Cash, cash equivalents, and restricted cash at end of period $ 69.0 $ 3.0 $ 83.8 $ — $ 155.8

Basis of Presentation - Net Ope

Basis of Presentation - Net Operating Revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 1,124	$ 1,046
Inpatient Rehabilitation Segment [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	870.1	840.3
Home Health and Hospice Segment [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	253.9	205.7
Net operating revenues [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	1,124	1,046
Net operating revenues [Member] | Other income [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	12.3	10
Net operating revenues [Member] | Inpatient Rehabilitation Segment [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	870.1	840.3
Net operating revenues [Member] | Inpatient Rehabilitation Segment [Member] | Other income [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	12	9.8
Net operating revenues [Member] | Home Health and Hospice Segment [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	253.9	205.7
Net operating revenues [Member] | Home Health and Hospice Segment [Member] | Other income [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	0.3	0.2
Net operating revenues [Member] | Third-Party Payor [Member] | Medicare [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	853.7	801.4
Net operating revenues [Member] | Third-Party Payor [Member] | Medicare Advantage [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	110.7	92.5
Net operating revenues [Member] | Third-Party Payor [Member] | Managed Care [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	91.9	92.6
Net operating revenues [Member] | Third-Party Payor [Member] | Medicaid [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	30.5	25.2
Net operating revenues [Member] | Third-Party Payor [Member] | Other third-party payors [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	10	12
Net operating revenues [Member] | Third-Party Payor [Member] | Workers' compensation [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	8.4	7.5
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Medicare [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	638.9	624.5
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Medicare Advantage [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	85.2	72.5
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Managed Care [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	83.5	85
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Medicaid [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	26.2	24.7
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Other third-party payors [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	10	12
Net operating revenues [Member] | Third-Party Payor [Member] | Inpatient Rehabilitation Segment [Member] | Workers' compensation [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	8.2	7.4
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Medicare [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	214.8	176.9
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Medicare Advantage [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	25.5	20
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Managed Care [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	8.4	7.6
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Medicaid [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	4.3	0.5
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Other third-party payors [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	0	0
Net operating revenues [Member] | Third-Party Payor [Member] | Home Health and Hospice Segment [Member] | Workers' compensation [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	0.2	0.1
Net operating revenues [Member] | Self-Pay [Member] | Patients [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	6.5	4.8
Net operating revenues [Member] | Self-Pay [Member] | Inpatient Rehabilitation Segment [Member] | Patients [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	6.1	4.4
Net operating revenues [Member] | Self-Pay [Member] | Home Health and Hospice Segment [Member] | Patients [Member] | Payor Source [Member]
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 0.4	$ 0.4

Basis of Presentation Basis of

Basis of Presentation Basis of Presentation - Revision of Previously Issued Financial Statements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,616.5	$ 1,409.9	$ 1,557	$ 1,395.4
Change in fair value	(20.3)	(42.2)
Capital in Excess of Par Value
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,551.3	2,685.9	2,588.7	2,747.4
Change in fair value	(20.3)	(42.2)
Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ (782.9)	(1,093.7)	$ (885.2)	$ (1,176.2)
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		1,440.8
Change in fair value		(40.5)
As Reported [Member] | Capital in Excess of Par Value
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		2,731.6
As Reported [Member] | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		(1,108.5)
Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		(30.9)
Change in fair value		(1.7)
Adjustment [Member] | Capital in Excess of Par Value
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		(45.7)
Adjustment [Member] | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		$ 14.8

Basis of Presentation Basis o_2

Basis of Presentation Basis of Presentation - Textual (Details) $ in Millions	Mar. 31, 2019USD ($)state		Dec. 31, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of states in which entity operates | state	37
Total assets	$ 5,583.8	[1]	$ 5,175
Liabilities	3,694.3		3,356.3
Capital in excess of par value	1,616.5		1,557	$ 1,409.9	$ 1,395.4
Adoption of ASC 842 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total assets	349
Liabilities	347
Capital in Excess of Par Value
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capital in excess of par value	2,551.3		$ 2,588.7	$ 2,685.9	$ 2,747.4
Capital in Excess of Par Value | Adoption of ASC 842 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capital in excess of par value	$ 2
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Business Combinations - Textual

Business Combinations - Textual (Details) - Home Health and Hospice Segment [Member] $ in Millions	1 Months Ended	3 Months Ended
	Mar. 31, 2019USD ($)location	Mar. 31, 2019USD ($)location	Mar. 01, 2019location
Alacare [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross | $	$ 217.5
Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Business Acquisition, Goodwill, Expected Tax Deductible Amount | $	$ 10.8	$ 10.8
Noncompete agreements [Member] | Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		5 years
Certificates of need [Member] | Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		10 years
License [Member] | Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		10 years
Home health [Member] | Alacare [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity	23	23
Home health [Member] | Care Resource Group [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity			2
Hospice [Member] | Alacare [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity	23	23

Business Combinations - Fair Va

Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill	$ 2,111.6	$ 2,100.8
Home Health and Hospice Segment [Member] | Certificates of need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	2
Home Health and Hospice Segment [Member] | Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Goodwill	10.8
Other assets acquired	0.2
Total assets acquired	14
Accrued payroll	(0.1)
Other current liabilities	(0.1)
Other long-term liabilities	(0.1)
Total liabilities assumed	(0.3)
Net assets acquired	13.7
Home Health and Hospice Segment [Member] | Tidewater and Care Resource Group [Member] | Noncompete agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.2
Home Health and Hospice Segment [Member] | Tidewater and Care Resource Group [Member] | License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 0.8

Business Combinations - Net Cas

Business Combinations - Net Cash Paid for Acquisitions (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Business Acquisition [Line Items]
Net cash paid for acquisition	$ 13.7	$ 0.6
Home Health and Hospice Segment [Member] | Tidewater and Care Resource Group [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	3.2	0.1
Goodwill	10.8	0.5
Fair value of liabilities assumed	(0.3)	0
Net cash paid for acquisition	$ 13.7	$ 0.6

Business Combinations - Pro For

Business Combinations - Pro Forma Results of Operation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Business Acquisition [Line Items]
Combined entity: Supplemental pro forma, Net Operating Revenues	$ 1,126	$ 1,048.4
Combined entity: Supplemental pro forma, Net Income Attributable to Encompass Health	102.5	$ 84
Tidewater and Care Resource Group [Member] | Home Health and Hospice Segment [Member]
Business Acquisition [Line Items]
Acquired entity only: Actual from acquisition date to March 31, 2019, Net Operating Revenues	1
Acquired entities only: Actual from acquisition date to March 31, 2019, Net Income Attributable to Encompass Health	$ (0.1)

Variable Interest Entities - Te

Variable Interest Entities - Textual (Details) - Consolidated Limited Partnership-like Entities [Member] - entity	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Variable Interest Entity [Line Items]
Number of consolidated limited partnership-like entities	8	8
Minimum [Member]
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	50.00%
Maximum [Member]
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	75.00%

Variable Interest Entities - Ta

Variable Interest Entities - Table 1 (Details) - USD ($) $ in Millions	Mar. 31, 2019		Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 56.1		$ 69.2	$ 86.4	$ 54.4
Accounts receivable	500.6		467.7
Other current assets	67		66.2
Total current assets	682.7		662.1
Property and equipment, net	1,736.2		1,634.8
Operating lease right-of-use assets	284.9		0
Goodwill	2,111.6		2,100.8
Intangible assets, net	435.4		443.4
Other long-term assets	292.5		291
Total assets	5,583.8	[1]	5,175
Current portion of long-term debt	37.3		35.8
Current operating lease liabilities	48.3		0
Accounts payable	94.7		90
Total current liabilities	768.2		672.5
Long-term debt, net of current portion	2,521.8		2,478.6
Long-term operating lease liabilities	245		0
Total Liabilities	3,694.3		3,356.3
Consolidated VIEs [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	0.7		0.3
Accounts receivable	31		31
Other current assets	5.9		4.9
Total current assets	37.6		36.2
Property and equipment, net	121.2		111.5
Operating lease right-of-use assets	7.2		0
Goodwill	15.9		15.9
Intangible assets, net	4		4.3
Other long-term assets	30.3		29.6
Total assets	216.2		197.5
Current portion of long-term debt	0.7		0.6
Current operating lease liabilities	1.4		0
Accounts payable	5.6		5.2
Accrued expenses and other current liabilities	37.7		45
Total current liabilities	45.4		50.8
Long-term debt, net of current portion	11.1		0
Long-term operating lease liabilities	5.7		0
Total Liabilities	$ 62.2		$ 50.8
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Leases - Textuals (Details)

Leases - Textuals (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Lessee, Lease, Description [Line Items]
Finance lease right-of-use asset accumulated depreciation	$ 95.6
Minimum [Member]
Lessee, Lease, Description [Line Items]
Operating and finance lease contract term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Operating and finance lease contract term	25 years

Leases - Table 1 (Details)

Leases - Table 1 (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Lease, Cost [Abstract]
Operating lease cost	$ 17.5
Amortization of right-of-use assets	11.9
Interest of lease liabilities	8.1
Total finance lease cost	20
Short-term and variable lease cost	0.3
Sublease income	(0.8)
Total lease cost	$ 37

Leases - Table 2 (Details)

Leases - Table 2 (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating lease right-of-use assets	$ 284.9	$ 0
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet
Finance lease, Property and equipment, net	$ 344
Total leased assets	628.9
Current operating lease liabilities	$ 48.3	0
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
Finance lease, Current portion of long-term debt	$ 18.2
Long-term operating lease liabilities	$ 245	$ 0
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtAndCapitalLeaseObligations
Finance lease, long-term debt, net of current portion	$ 381.9
Total lease liabilities	$ 693.4

Leases - Table 3 (Details)

Leases - Table 3 (Details)	Mar. 31, 2019Rate
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	8 years 7 months 20 days
Finance Lease, Weighted Average Remaining Lease Term	13 years 6 months 7 days
Operating Lease, Weighted Average Discount Rate, Percent	6.30%
Finance Lease, Weighted Average Discount Rate, Percent	8.20%

Leases - Table 4 (Details)

Leases - Table 4 (Details) $ in Millions	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating Leases - April 1 through December 31, 2019	$ 48.1
Finance Leases - April 1 through December 31, 2019	37.8
Operating Leases - 2020	58.6
Finance Leases - 2020	49.9
Operating Leases - 2021	51
Finance Leases - 2021	48
Operating Leases - 2022	40.8
Finance Leases - 2022	57.6
Operating Leases - 2023	35.4
Finance Leases - 2023	43.7
Operating Leases - 2024	31.3
Finance Leases - 2024	58.1
Operating Leases - 2025 and Thereafter	129.7
Finance Lease - 2025 and Thereafter	391.4
Operating Leases - Total lease payments	394.9
Finance Leases - Total lease payments	686.5
Less: Operating Lease, Interest Portion	(101.6)
Less: Finance Lease, Interest Portion	(286.4)
Total Operating Lease Liabilities	293.3
Total Finance Lease Liabilities	$ 400.1

Leases - Table 5 (Details)

Leases - Table 5 (Details) $ in Millions	Dec. 31, 2018USD ($)
Leases [Abstract]
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 71.4
Capital Leases, Future Minimum Payments Due, Next Twelve Months	36.2
Operating Leases, Future Minimum Payments, Due in Two Years	65.8
Capital Leases, Future Minimum Payments Due in Two Years	32.3
Operating Leases, Future Minimum Payments, Due in Three Years	54.3
Capital Leases, Future Minimum Payments Due in Three Years	30.3
Operating Leases, Future Minimum Payments, Due in Four Years	41
Capital Leases, Future Minimum Payments Due in Four Years	28.7
Operating Leases, Future Minimum Payments, Due in Five Years	35.3
Capital Leases, Future Minimum Payments Due in Five Years	28
Operating Leases, Future Minimum Payments, Due Thereafter	148.2
Capital Leases, Future Minimum Payments Due Thereafter	299.7
Operating Leases, Future Minimum Payments Due	416
Capital Leases, Future Minimum Payments Due	455.2
Capital Leases, Future Minimum Payments, Interest Included in Payments	(191.4)
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	$ 263.8

Leases - Table 6 (Details)

Leases - Table 6 (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 17.2
Operating cash flows from finance leases	8
Financing cash flows from finance leases	2.8
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	5.5
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 3.1

Investments in and Advances t_3

Investments in and Advances to Nonconsolidated Affiliates - Textual (Details) $ in Millions	Mar. 31, 2019USD ($)entity	Dec. 31, 2018USD ($)
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Investments in and advances to nonconsolidated affiliates | $	$ 12.5	$ 12.2
Number of partially owned subsidiaries	5
Number of partially owned general or limited partnerships, limited liability companies of joint ventures	4
Minimum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Ownership interest in affiliates (percent)	19.00%
Maximum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Ownership interest in affiliates (percent)	60.00%

Investments In and Advances t_4

Investments In and Advances to Nonconsolidated Affiliates - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Net operating revenues	$ 11.6	$ 11
Operating expenses	(6.8)	(7.6)
Income from continuing operations, net of tax	4.9	3.4
Net income	$ 4.9	$ 3.4

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period	$ 261.7
Net income attributable to noncontrolling interests	4	$ 2.8
Distributions declared	(15.3)	(17.7)
Reclassification to noncontrolling interests	11.2	0
Change in fair value	(20.3)	(42.2)
Balance at end of period	273
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period	261.7	220.9
Net income attributable to noncontrolling interests	4	2.8
Distributions declared	(1.8)	(2.2)
Purchase of redeemable noncontrolling interests	0	(65.1)
Change in fair value	20.3	42.2
Balance at end of period	$ 273	$ 198.6

Redeemable Noncontrolling Int_4

Redeemable Noncontrolling Interests - Table 2 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Noncontrolling Interest [Abstract]
Net income attributable to nonredeemable noncontrolling interests	$ 18.9	$ 18.6
Net income attributable to redeemable noncontrolling interests	4	2.8
Net income attributable to noncontrolling interests	$ 22.9	$ 21.4

Redeemable Noncontrolling Int_5

Redeemable Noncontrolling Interests Redeemable Noncontrolling Interests - Textuals (Details) - USD ($) $ in Millions	Feb. 21, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2014
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests		$ 273		$ 261.7
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	5.60%
Purchase of redeemable noncontrolling interests	$ 65	0	$ 65.1
EHHI [Member]
Noncontrolling Interest [Line Items]
Outstanding common stock of Holdings, Fair Value		$ 245
EHHI [Member] | Home Health and Hospice Segment [Member]
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests					$ 64
Subsidiary's common stock held by subsidiary 's management, Percent					16.70%

Fair Value Measurements - Table

Fair Value Measurements - Table 1 (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Valuation, Market Approach [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Restricted marketable securities	$ 63.6	$ 62
Valuation, Market Approach [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Restricted marketable securities	6.7	6.4
Valuation, Market Approach [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Restricted marketable securities	56.9	55.6
Valuation, Market Approach [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Restricted marketable securities	0	0
Valuation, Income Approach [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	273	261.7
Valuation, Income Approach [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	0	0
Valuation, Income Approach [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	0	0
Valuation, Income Approach [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	$ 273	$ 261.7

Fair Value Measurements - Textu

Fair Value Measurements - Textuals (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gains or losses related to non-financial assets and liabilities	$ 0	$ 0
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument interest rate (percent)	5.125%		5.125%
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument interest rate (percent)	5.75%		5.75%
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument interest rate (percent)	5.75%		5.75%

Fair Value Measurements - Tab_2

Fair Value Measurements - Table 2 (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Revolving Credit Facility [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 25	$ 30
Revolving Credit Facility [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	25	30
Letters of Credit [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	0	0
Letters of Credit [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	39.1	37.4
Term Loan Facilities [Member] | Term Loan Facilities [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	276.4	280.1
Term Loan Facilities [Member] | Term Loan Facilities [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 277.5	$ 281.3
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.125%	5.125%
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 296.8	$ 296.6
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 305.3	$ 298.5
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.75%	5.75%
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 1,194.8	$ 1,194.7
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 1,221	$ 1,200
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.75%	5.75%
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 345.2	$ 345
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	357.9	339.5
Other Notes Payable [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	20.8	104.2
Other Notes Payable [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 20.8	$ 104.2

Share-Based Payments Textual (D

Share-Based Payments Textual (Details) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 28, 2019	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash paid for SARs exercised		$ 13
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)	0.4
Restricted Stock [Member] | Service Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)	0.1
Restricted Stock [Member] | Service and Performance Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance measurement period	2 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (shares)	0.1
Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of SARs		$ 86

Income Taxes - Textual (Details

Income Taxes - Textual (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Income Tax Contingency [Line Items]
Provision for income tax expense	$ 30.8	$ 30
Net deferred tax assets	40.5
Valuation allowance	34.5
Additional tax benefits due to approval of accounting method change			$ 51.3
Gross unrecognized tax benefits	0.9			$ 0.9
Gross unrecognized tax benefits that would impact effective tax rate if recognized	0.9			$ 0.9
Amount of decrease in unrecognized tax benefit to be released	0.5
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 64.5

Earnings per Common Share - Tab

Earnings per Common Share - Table 1 (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Basic Numerator:
Income from continuing operations	$ 125.7	$ 105.7
Less: Net income attributable to noncontrolling interests included in continuing operations	(22.9)	(21.4)
Less: Income allocated to participating securities	(0.4)	(0.3)
Income from continuing operations attributable to Encompass Health common shareholders	102.4	84
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net income attributable to Encompass Health common shareholders	$ 101.9	$ 83.5
Basic Denominator:
Basic weighted average common shares outstanding (shares)	98.4	97.8
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.05	$ 0.86
Discontinued operations (in dollars per share)	(0.01)	(0.01)
Net Income (in dollars per share)	$ 1.04	$ 0.85
Diluted Numerator
Income from continuing operations	$ 125.7	$ 105.7
Less: Net income attributable to noncontrolling interests included in continuing operations	(22.9)	(21.4)
Income from continuing operations attributable to Encompass Health common shareholders	102.8	84.3
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net income attributable to Encompass Health common shareholders	$ 102.3	$ 83.8
Diluted Denominator
Diluted weighted average common shares outstanding (shares)	99.7	99.4
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations (in dollars per share)	$ 1.04	$ 0.85
Discontinued operations (in dollars per share)	(0.01)	(0.01)
Net income (in dollars per share)	$ 1.03	$ 0.84

Earnings per Common Share - T_2

Earnings per Common Share - Table 2 (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding (shares)	98.4	97.8
Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants (shares)	1.3	1.6
Diluted weighted average common shares outstanding (shares)	99.7	99.4

Earnings per Common Share - Tex

Earnings per Common Share - Textual (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 15, 2019	Feb. 21, 2019	Jan. 15, 2019	Oct. 26, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Declared (in dollars per share)					$ 0.27	$ 0.25
Common Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Declared (in dollars per share)		$ 0.27		$ 0.27
Cash dividends per common share, Paid (in dollars per share)			$ 0.27
Common stock dividends accrued					$ 27.8		$ 28.4
Subsequent Event [Member] | Common Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Paid (in dollars per share)	$ 0.27

Contingencies and Other Commi_2

Contingencies and Other Commitments (Details) - Pending Litigation [Member] $ in Millions	May 18, 2016USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2019USD ($)	Feb. 28, 2015patient	Apr. 24, 2014facilities	Aug. 12, 2013facilities	Mar. 04, 2013patientfacilities
Honts lawsuit [Member]
Loss Contingencies [Line Items]
Number of hospitals involved in lawsuit | facilities						1
Punitive damages awarded in favor of plaintiff | $	$ 20
Portion of liability that would be covered through captive insurance subsidiary | $		$ 6
HHS-OIG Investigation [Member]
Loss Contingencies [Line Items]
Number of hospitals that received subpoenas | facilities					7		4
Number of patient medical records requested for each hospital in subpoenas | patient							100
Number of hospitals that received supplemental subpoenas | facilities					2
Number of additional patient medical records requested | patient				70
Compliance threshold under Health Care Act (percent)			60.00%
Loss Contingency Accrual | $			$ 48

Segment Reporting - Textuals (D

Segment Reporting - Textuals (Details)	3 Months Ended
	Mar. 31, 2019locationfacilitiessegmentstate
Segment Reporting Information [Line Items]
Number of operating segments | segment	2
Number of states in which entity operates | state	37
Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	32
Number of inpatient rehabilitation hospitals operated	130
Number of hospitals or agencies operated as a joint venture	1
Number of solely owned inpatient rehabilitation hospitals	85
Number of inpatient rehabilitation units under management contracts	5
Number of jointly owned inpatient rehabilitation hospitals	45
Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	31
Number of hospitals or agencies operated as a joint venture	2
Number of solely owned hospital based home health and hospice locations | location	272
Number of home health locations | location	221
Number of hospice locations | location	59
Number of jointly owned hospital based home health and hospice locations | location	8
Minimum [Member] | Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Joint venture ownership percentage	50.00%
Minimum [Member] | Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Joint venture ownership percentage	50.00%
Maximum [Member] | Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Joint venture ownership percentage	97.50%
Maximum [Member] | Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Joint venture ownership percentage	81.00%

Segment Reporting - Table 1 (De

Segment Reporting - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Net operating revenues	$ 1,124	$ 1,046
Costs and Expenses [Abstract]
Salaries and benefits	620.8	570.2
Other operating expenses	150.1	141.2
Supplies	40.1	39.9
Occupancy costs	19.6	18.6
Total operating expenses	936.5	876.9
Other income	(3.7)	0.1
Equity in net income of nonconsolidated affiliates	(2.5)	(2.3)
Net income attributable to noncontrolling interests	22.9	21.4
Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Net operating revenues	870.1	840.3
Costs and Expenses [Abstract]
Salaries and benefits	445	424.2
Other operating expenses	127.6	122.9
Supplies	35.6	35.9
Occupancy costs	15.8	15.5
Total operating expenses	624	598.5
Other income	(2.8)	(0.5)
Equity in net income of nonconsolidated affiliates	(2.1)	(2)
Net income attributable to noncontrolling interests	21	20.5
Segment Adjusted EBITDA	230	223.8
Capital Expenditures	70.4	62.2
Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Net operating revenues	253.9	205.7
Costs and Expenses [Abstract]
Cost of services sold (excluding depreciation and amortization)	116.5	98.6
Support and overhead costs	88.8	72
Total operating expenses	205.3	170.6
Other income	0	0
Equity in net income of nonconsolidated affiliates	(0.4)	(0.3)
Net income attributable to noncontrolling interests	2.7	1.9
Segment Adjusted EBITDA	46.3	33.5
Capital Expenditures	$ 4.5	$ 1.7

Segment Reporting - Table 2 (De

Segment Reporting - Table 2 (Details) - USD ($) $ in Millions	Mar. 31, 2019		Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 5,583.8	[1]	$ 5,175
Investments in and advances to nonconsolidated affiliates	12.5		12.2
Inpatient Rehabilitation Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	4,250.5		3,900.9
Investments in and advances to nonconsolidated affiliates	9.4		9.5
Home Health and Hospice Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,366.8		1,314.6
Investments in and advances to nonconsolidated affiliates	$ 3.1		$ 2.7
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Segment Reporting - Table 3 (De

Segment Reporting - Table 3 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	$ (53.4)	$ (61.1)
Depreciation and amortization	(52.5)	(45.9)
Net income attributable to noncontrolling interests	22.9	21.4
Income from continuing operations before income tax expense	156.5	135.7
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total segment Adjusted EBITDA	276.3	257.3
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	(53.4)	(61.1)
Depreciation and amortization	(52.5)	(45.9)
Loss on disposal of assets	(1.1)	(0.8)
Interest expense and amortization of debt discounts and fees	(37.2)	(35.6)
Net income attributable to noncontrolling interests	22.9	21.4
SARs mark-to-market impact on noncontrolling interests	0.8	1
Change in fair market value of equity securities	0.9	(0.6)
Payroll taxes on SARs exercise	$ (0.2)	$ 0

Segment Reporting - Table 4 (De

Segment Reporting - Table 4 (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019		Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	$ 5,583.8	[1]	$ 5,175
Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets	(33.5)		(40.5)
Total assets	5,583.8	[1]	5,175
Operating Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	5,617.3		5,215.5
Total assets	$ 5,617.3		$ 5,215.5
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Segment Reporting - Table 5 (De

Segment Reporting - Table 5 (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 1,124	$ 1,046
Inpatient Rehabilitation Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	870.1	840.3
Inpatient Rehabilitation Segment [Member] | Inpatient [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	847.6	817.1
Inpatient Rehabilitation Segment [Member] | Outpatient and other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	22.5	23.2
Home Health and Hospice Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	253.9	205.7
Home Health and Hospice Segment [Member] | Home health [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	219.5	185.3
Home Health and Hospice Segment [Member] | Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 34.4	$ 20.4

Condensed Consolidating Finan_3

Condensed Consolidating Financial Information - Narrative (Details)	Mar. 31, 2019
Condensed Financial Information Disclosure [Abstract]
Senior secured leverage ratio maximum	2
Consolidated coverage ratio minimum	2

Condensed Consolidating Finan_4

Condensed Consolidating Financial Information - Income Statement Tables (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Condensed Consolidating Statements of Operations
Net operating revenues	$ 1,124	$ 1,046
Operating expenses:
Salaries and benefits	620.8	570.2
Other operating expenses	150.1	141.2
Occupancy costs	19.6	18.6
Supplies	40.1	39.9
General and administrative expenses	53.4	61.1
Depreciation and amortization	52.5	45.9
Total operating expenses	936.5	876.9
Interest expense and amortization of debt discounts and fees	37.2	35.6
Other (income) loss	(3.7)	0.1
Equity in net income of nonconsolidated affiliates	(2.5)	(2.3)
Equity in net income of consolidated affiliates	0	0
Management fees	0	0
Income from continuing operations before income tax expense	156.5	135.7
Provision for income tax (benefit) expense	30.8	30
Income from continuing operations	125.7	105.7
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net and comprehensive income	125.2	105.2
Less: Net and comprehensive income attributable to noncontrolling interests	(22.9)	(21.4)
Net and comprehensive income attributable to Encompass Health	102.3	83.8
Encompass Health Corporation [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	5.1	5.4
Operating expenses:
Salaries and benefits	15.9	13.2
Other operating expenses	10.3	8.4
Occupancy costs	0.5	0.5
Supplies	0	0
General and administrative expenses	39.9	39.4
Depreciation and amortization	5	2
Total operating expenses	71.6	63.5
Interest expense and amortization of debt discounts and fees	30.1	29.8
Other (income) loss	(7.7)	(4.7)
Equity in net income of nonconsolidated affiliates	0	0
Equity in net income of consolidated affiliates	(130.2)	(112.3)
Management fees	(39.8)	(38.4)
Income from continuing operations before income tax expense	81.1	67.5
Provision for income tax (benefit) expense	(21.7)	(16.8)
Income from continuing operations	102.8	84.3
Loss from discontinued operations, net of tax	(0.5)	(0.5)
Net and comprehensive income	102.3	83.8
Less: Net and comprehensive income attributable to noncontrolling interests	0	0
Net and comprehensive income attributable to Encompass Health	102.3	83.8
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	606.5	594.6
Operating expenses:
Salaries and benefits	288.9	282.4
Other operating expenses	84.7	84.6
Occupancy costs	24.9	23.8
Supplies	24	24.7
General and administrative expenses	0	0
Depreciation and amortization	26.3	26.6
Total operating expenses	448.8	442.1
Interest expense and amortization of debt discounts and fees	6.2	5.7
Other (income) loss	(0.3)	(0.2)
Equity in net income of nonconsolidated affiliates	(2.1)	(1.9)
Equity in net income of consolidated affiliates	(17)	(16.5)
Management fees	29.5	28.8
Income from continuing operations before income tax expense	141.4	136.6
Provision for income tax (benefit) expense	37.8	36.8
Income from continuing operations	103.6	99.8
Loss from discontinued operations, net of tax	0	0
Net and comprehensive income	103.6	99.8
Less: Net and comprehensive income attributable to noncontrolling interests	0	0
Net and comprehensive income attributable to Encompass Health	103.6	99.8
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	546	478.6
Operating expenses:
Salaries and benefits	321.1	280
Other operating expenses	67.6	60.6
Occupancy costs	10.2	9.1
Supplies	16.1	15.2
General and administrative expenses	13.5	21.7
Depreciation and amortization	21.2	17.3
Total operating expenses	449.7	403.9
Interest expense and amortization of debt discounts and fees	7.7	5.2
Other (income) loss	(2.5)	(0.1)
Equity in net income of nonconsolidated affiliates	(0.4)	(0.4)
Equity in net income of consolidated affiliates	0	0
Management fees	10.3	9.6
Income from continuing operations before income tax expense	81.2	60.4
Provision for income tax (benefit) expense	14.7	10
Income from continuing operations	66.5	50.4
Loss from discontinued operations, net of tax	0	0
Net and comprehensive income	66.5	50.4
Less: Net and comprehensive income attributable to noncontrolling interests	(22.9)	(21.4)
Net and comprehensive income attributable to Encompass Health	43.6	29
Consolidation, Eliminations [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	(33.6)	(32.6)
Operating expenses:
Salaries and benefits	(5.1)	(5.4)
Other operating expenses	(12.5)	(12.4)
Occupancy costs	(16)	(14.8)
Supplies	0	0
General and administrative expenses	0	0
Depreciation and amortization	0	0
Total operating expenses	(33.6)	(32.6)
Interest expense and amortization of debt discounts and fees	(6.8)	(5.1)
Other (income) loss	6.8	5.1
Equity in net income of nonconsolidated affiliates	0	0
Equity in net income of consolidated affiliates	147.2	128.8
Management fees	0	0
Income from continuing operations before income tax expense	(147.2)	(128.8)
Provision for income tax (benefit) expense	0	0
Income from continuing operations	(147.2)	(128.8)
Loss from discontinued operations, net of tax	0	0
Net and comprehensive income	(147.2)	(128.8)
Less: Net and comprehensive income attributable to noncontrolling interests	0	0
Net and comprehensive income attributable to Encompass Health	$ (147.2)	$ (128.8)

Condensed Consolidating Finan_5

Condensed Consolidating Financial Information - Balance Sheet Tables (Details) - USD ($) $ in Millions	Mar. 31, 2019		Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 56.1		$ 69.2	$ 86.4	$ 54.4
Restricted cash	59		59	69.4	62.4
Accounts receivable	500.6		467.7
Other current assets	67		66.2
Total current assets	682.7		662.1
Property and equipment, net	1,736.2		1,634.8
Operating lease right-of-use assets	284.9		0
Goodwill	2,111.6		2,100.8
Intangible assets, net	435.4		443.4
Deferred income tax assets	40.5		42.9
Other long-term assets	292.5		291
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	0		0
Total assets	5,583.8	[1]	5,175
Current liabilities:
Current portion of long-term debt	37.3		35.8
Current operating lease liabilities	48.3		0
Accounts payable	94.7		90
Accrued expenses and other current liabilities	587.9		546.7
Total current liabilities	768.2		672.5
Long-term debt, net of current portion	2,521.8		2,478.6
Long-term operating lease liabilities	245		0
Intercompany notes payable	0		0
Other long-term liabilities	159.3		205.2
Intercompany payable	0		0
Total Liabilities	3,694.3		3,356.3
Commitments and contingencies
Redeemable noncontrolling interests	273		261.7
Shareholders' equity:
Encompass Health shareholders’ equity	1,314.3		1,276.7
Noncontrolling interests	302.2		280.3
Total shareholders’ equity	1,616.5		1,557	1,409.9	1,395.4
Total liabilities and shareholders' equity	5,583.8	[1]	5,175
Encompass Health Corporation [Member]
Current assets:
Cash and cash equivalents	34.7		41.5	69	34.3
Restricted cash	0		0	0	0
Accounts receivable	0		0
Other current assets	69.3		36.3
Total current assets	104		77.8
Property and equipment, net	126		123.9
Operating lease right-of-use assets	15.2
Goodwill	0		0
Intangible assets, net	20.5		21.4
Deferred income tax assets	38.5		47.9
Other long-term assets	50.7		47.9
Intercompany notes receivable	540.4		535.3
Intercompany receivable and investments in consolidated affiliates	2,957.6		2,904.4
Total assets	3,852.9		3,758.6
Current liabilities:
Current portion of long-term debt	35.4		35
Current operating lease liabilities	2.5
Accounts payable	9.5		8.9
Accrued expenses and other current liabilities	262.2		211.8
Total current liabilities	309.6		255.7
Long-term debt, net of current portion	2,176.8		2,188.7
Long-term operating lease liabilities	12.9
Intercompany notes payable	0		0
Other long-term liabilities	39.3		37.5
Intercompany payable	0		0
Total Liabilities	2,538.6		2,481.9
Redeemable noncontrolling interests	0		0
Shareholders' equity:
Encompass Health shareholders’ equity	1,314.3		1,276.7
Noncontrolling interests	0		0
Total shareholders’ equity	1,314.3		1,276.7
Total liabilities and shareholders' equity	3,852.9		3,758.6
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	3.5		3	3	3
Restricted cash	0		0	0	0
Accounts receivable	292.5		270.7
Other current assets	32.2		17.6
Total current assets	328.2		291.3
Property and equipment, net	1,090.6		1,041.5
Operating lease right-of-use assets	176.6
Goodwill	912.2		912.2
Intangible assets, net	93.4		96.5
Deferred income tax assets	28.9		28.9
Other long-term assets	95.4		101.3
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	546.6		456.8
Total assets	3,271.9		2,928.5
Current liabilities:
Current portion of long-term debt	8.5		7.6
Current operating lease liabilities	25.6
Accounts payable	48.7		46.4
Accrued expenses and other current liabilities	86.4		76.4
Total current liabilities	169.2		130.4
Long-term debt, net of current portion	292.1		262.1
Long-term operating lease liabilities	155
Intercompany notes payable	0		0
Other long-term liabilities	10.8		17.1
Intercompany payable	0		0
Total Liabilities	627.1		409.6
Redeemable noncontrolling interests	0		0
Shareholders' equity:
Encompass Health shareholders’ equity	2,644.8		2,518.9
Noncontrolling interests	0		0
Total shareholders’ equity	2,644.8		2,518.9
Total liabilities and shareholders' equity	3,271.9		2,928.5
Nonguarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	17.9		24.7	14.4	17.1
Restricted cash	59		59	69.4	62.4
Accounts receivable	208.1		197
Other current assets	67.6		31.1
Total current assets	352.6		311.8
Property and equipment, net	519.6		469.4
Operating lease right-of-use assets	122.7
Goodwill	1,199.4		1,188.6
Intangible assets, net	321.5		325.5
Deferred income tax assets	0		0
Other long-term assets	146.4		141.8
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	0		0
Total assets	2,662.2		2,437.1
Current liabilities:
Current portion of long-term debt	10.9		10.7
Current operating lease liabilities	27.5
Accounts payable	36.5		34.7
Accrued expenses and other current liabilities	323.9		259.8
Total current liabilities	398.8		305.2
Long-term debt, net of current portion	52.9		27.8
Long-term operating lease liabilities	99.4
Intercompany notes payable	540.4		535.3
Other long-term liabilities	136		184.4
Intercompany payable	64.6		53.3
Total Liabilities	1,292.1		1,106
Redeemable noncontrolling interests	273		261.7
Shareholders' equity:
Encompass Health shareholders’ equity	794.9		789.1
Noncontrolling interests	302.2		280.3
Total shareholders’ equity	1,097.1		1,069.4
Total liabilities and shareholders' equity	2,662.2		2,437.1
Consolidation, Eliminations [Member]
Current assets:
Cash and cash equivalents	0		0	0	0
Restricted cash	0		0	$ 0	$ 0
Accounts receivable	0		0
Other current assets	(102.1)		(18.8)
Total current assets	(102.1)		(18.8)
Property and equipment, net	0		0
Operating lease right-of-use assets	(29.6)
Goodwill	0		0
Intangible assets, net	0		0
Deferred income tax assets	(26.9)		(33.9)
Other long-term assets	0		0
Intercompany notes receivable	(540.4)		(535.3)
Intercompany receivable and investments in consolidated affiliates	(3,504.2)		(3,361.2)
Total assets	(4,203.2)		(3,949.2)
Current liabilities:
Current portion of long-term debt	(17.5)		(17.5)
Current operating lease liabilities	(7.3)
Accounts payable	0		0
Accrued expenses and other current liabilities	(84.6)		(1.3)
Total current liabilities	(109.4)		(18.8)
Long-term debt, net of current portion	0		0
Long-term operating lease liabilities	(22.3)
Intercompany notes payable	(540.4)		(535.3)
Other long-term liabilities	(26.8)		(33.8)
Intercompany payable	(64.6)		(53.3)
Total Liabilities	(763.5)		(641.2)
Redeemable noncontrolling interests	0		0
Shareholders' equity:
Encompass Health shareholders’ equity	(3,439.7)		(3,308)
Noncontrolling interests	0		0
Total shareholders’ equity	(3,439.7)		(3,308)
Total liabilities and shareholders' equity	$ (4,203.2)		$ (3,949.2)
[1]	Our consolidated assets as of March 31, 2019 and December 31, 2018 include total assets of variable interest entities of $216.2 million and $197.5 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March 31, 2019 and December 31, 2018 include total liabilities of the variable interest entities of $62.2 million and $50.8 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidating Finan_6

Condensed Consolidating Financial Information - Cash Flow Statement Tables (Details) - USD ($) $ in Millions	Feb. 21, 2018	Mar. 31, 2019	Mar. 31, 2018
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities		$ 159.9	$ 216.3
Cash flows from investing activities:
Purchases of property and equipment		(72.3)	(59.9)
Acquisitions of businesses, net of cash acquired		(13.7)	(0.6)
Funding of intercompany note receivable		0
Proceeds from repayment of intercompany notes receivable		0	0
Other, net		(5.5)	(0.1)
Net cash used in investing activities		(91.5)	(60.6)
Cash flows from financing activities:
Principal borrowings on intercompany note payable		0
Principal payments on intercompany note payable		0	0
Borrowings on revolving credit facility		25	95
Payments on revolving credit facility		(30)	(95)
Dividends paid on common stock		(28.3)	(25.4)
Purchase of equity interests in consolidated affiliates	$ (65)	0	(65.1)
Distributions paid to noncontrolling interests of consolidated affiliates		(19.5)	(15.4)
Taxes paid on behalf of employees for shares withheld		(15.9)	(8.3)
Other, net		(13)	(2.5)
Change in intercompany advances		0	0
Net cash used in financing activities		(81.7)	(116.7)
(Decrease) increase in cash, cash equivalents, and restricted cash		(13.3)	39
Cash, cash equivalents, and restricted cash at beginning of period		133.5	116.8
Cash, cash equivalents, and restricted cash at end of period		120.2	155.8
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period		69.2	54.4
Restricted cash at beginning of period		59	62.4
Restricted cash included in other long-term assets at beginning of period		5.3	0
Cash, cash equivalents, and restricted cash at beginning of period		133.5	116.8
Cash and cash equivalents at end of period		56.1	86.4
Restricted cash at end of period		59	69.4
Restricted cash included in other long-term assets at end of period		5.1	0
Cash, cash equivalents, and restricted cash at end of period		120.2	155.8
Encompass Health Corporation [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities		18.6	10.2
Cash flows from investing activities:
Purchases of property and equipment		(6.8)	(12.3)
Acquisitions of businesses, net of cash acquired		0	0
Funding of intercompany note receivable		(8)
Proceeds from repayment of intercompany notes receivable		5	22
Other, net		(4)	(5.1)
Net cash used in investing activities		(13.8)	4.6
Cash flows from financing activities:
Principal borrowings on intercompany note payable		0
Principal payments on intercompany note payable		0	0
Borrowings on revolving credit facility		25	95
Payments on revolving credit facility		(30)	(95)
Dividends paid on common stock		(28.2)	(25.3)
Purchase of equity interests in consolidated affiliates			(65.1)
Distributions paid to noncontrolling interests of consolidated affiliates		0	0
Taxes paid on behalf of employees for shares withheld		(14.7)	(7.4)
Other, net		(14.7)	2.3
Change in intercompany advances		51	115.4
Net cash used in financing activities		(11.6)	19.9
(Decrease) increase in cash, cash equivalents, and restricted cash		(6.8)	34.7
Cash, cash equivalents, and restricted cash at beginning of period		41.5	34.3
Cash, cash equivalents, and restricted cash at end of period		34.7	69
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period		41.5	34.3
Restricted cash at beginning of period		0	0
Restricted cash included in other long-term assets at beginning of period		0
Cash, cash equivalents, and restricted cash at beginning of period		41.5	34.3
Cash and cash equivalents at end of period		34.7	69
Restricted cash at end of period		0	0
Restricted cash included in other long-term assets at end of period		0
Cash, cash equivalents, and restricted cash at end of period		34.7	69
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities		89.6	114.3
Cash flows from investing activities:
Purchases of property and equipment		(32.5)	(31.5)
Acquisitions of businesses, net of cash acquired		0	0
Proceeds from repayment of intercompany notes receivable		0	0
Other, net		(0.1)	(0.1)
Net cash used in investing activities		(32.6)	(31.6)
Cash flows from financing activities:
Principal borrowings on intercompany note payable		0
Principal payments on intercompany note payable		0	0
Borrowings on revolving credit facility		0	0
Payments on revolving credit facility		0	0
Dividends paid on common stock		0	0
Purchase of equity interests in consolidated affiliates			0
Distributions paid to noncontrolling interests of consolidated affiliates		0	0
Taxes paid on behalf of employees for shares withheld		0	0
Other, net		(2.1)	(2)
Change in intercompany advances		(54.4)	(80.7)
Net cash used in financing activities		(56.5)	(82.7)
(Decrease) increase in cash, cash equivalents, and restricted cash		0.5	0
Cash, cash equivalents, and restricted cash at beginning of period		3	3
Cash, cash equivalents, and restricted cash at end of period		3.5	3
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period		3	3
Restricted cash at beginning of period		0	0
Restricted cash included in other long-term assets at beginning of period		0
Cash, cash equivalents, and restricted cash at beginning of period		3	3
Cash and cash equivalents at end of period		3.5	3
Restricted cash at end of period		0	0
Restricted cash included in other long-term assets at end of period		0
Cash, cash equivalents, and restricted cash at end of period		3.5	3
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities		51.7	91.8
Cash flows from investing activities:
Purchases of property and equipment		(33)	(16.1)
Acquisitions of businesses, net of cash acquired		(13.7)	(0.6)
Proceeds from repayment of intercompany notes receivable		0	0
Other, net		(1.4)	5.1
Net cash used in investing activities		(48.1)	(11.6)
Cash flows from financing activities:
Principal borrowings on intercompany note payable		8
Principal payments on intercompany note payable		(5)	(22)
Borrowings on revolving credit facility		0	0
Payments on revolving credit facility		0	0
Dividends paid on common stock		(0.1)	(0.1)
Purchase of equity interests in consolidated affiliates			0
Distributions paid to noncontrolling interests of consolidated affiliates		(19.5)	(15.4)
Taxes paid on behalf of employees for shares withheld		(1.2)	(0.9)
Other, net		3.8	(2.8)
Change in intercompany advances		3.4	(34.7)
Net cash used in financing activities		(10.6)	(75.9)
(Decrease) increase in cash, cash equivalents, and restricted cash		(7)	4.3
Cash, cash equivalents, and restricted cash at beginning of period		89	79.5
Cash, cash equivalents, and restricted cash at end of period		82	83.8
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period		24.7	17.1
Restricted cash at beginning of period		59	62.4
Restricted cash included in other long-term assets at beginning of period		5.3
Cash, cash equivalents, and restricted cash at beginning of period		89	79.5
Cash and cash equivalents at end of period		17.9	14.4
Restricted cash at end of period		59	69.4
Restricted cash included in other long-term assets at end of period		5.1
Cash, cash equivalents, and restricted cash at end of period		82	83.8
Consolidation, Eliminations [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities		0	0
Cash flows from investing activities:
Purchases of property and equipment		0	0
Acquisitions of businesses, net of cash acquired		0	0
Funding of intercompany note receivable		8
Proceeds from repayment of intercompany notes receivable		(5)	(22)
Other, net		0	0
Net cash used in investing activities		3	(22)
Cash flows from financing activities:
Principal borrowings on intercompany note payable		(8)
Principal payments on intercompany note payable		5	22
Borrowings on revolving credit facility		0	0
Payments on revolving credit facility		0	0
Dividends paid on common stock		0	0
Purchase of equity interests in consolidated affiliates			0
Distributions paid to noncontrolling interests of consolidated affiliates		0	0
Taxes paid on behalf of employees for shares withheld		0	0
Other, net		0	0
Change in intercompany advances		0	0
Net cash used in financing activities		(3)	22
(Decrease) increase in cash, cash equivalents, and restricted cash		0	0
Cash, cash equivalents, and restricted cash at beginning of period		0	0
Cash, cash equivalents, and restricted cash at end of period		0	0
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period		0	0
Restricted cash at beginning of period		0	0
Restricted cash included in other long-term assets at beginning of period		0
Cash, cash equivalents, and restricted cash at beginning of period		0	0
Cash and cash equivalents at end of period		0	0
Restricted cash at end of period		0	0
Restricted cash included in other long-term assets at end of period		0
Cash, cash equivalents, and restricted cash at end of period		$ 0	$ 0